49. 全身性エリテマトーデス Disease details / Clinical trials / Drug dev / DR info

1 MG/KG cnto 136
   Centocor Research & Development, Inc.
      2007   Phase 1   NCT01702740   -
10 MG/KG cnto 136
   Centocor Research & Development, Inc.
      2007   Phase 1   NCT01702740   -
118-42-3
   Christine Bengtsson
      2015   Phase 2   EUCTR2014-005418-45-SE   Sweden
2-deoxy-2 [F-18] fluoro-2-D-glucose
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   -   NCT00029926   United States
4 MG/KG cnto 136
   Centocor Research & Development, Inc.
      2007   Phase 1   NCT01702740   -
81MG aspirin
   Oklahoma Medical Research Foundation
      2013   -   NCT01781611   United States
A-319
   Wuhan Union Hospital, China
      2024   Phase 1   NCT06400537   China
A-623
   Anthera Pharmaceuticals
      2011   Phase 2   NCT01305746   Argentina;Brazil;Chile;Colombia;Hong Kong;India;Mexico;Peru;Philippines;Taiwan;United States
      2010   Phase 2   NCT01162681   Argentina;Brazil;Chile;Colombia;Hong Kong;India;Mexico;Peru;Philippines;Taiwan;United States
AB-101
   Artiva Biotherapeutics, Inc.
      2024   Phase 1   NCT06265220   United States
   IRIS Research and Development, LLC
      2024   Phase 1   NCT06581562   United States
Abatacept
   Bristol Myers Squibb International Corporation
      2006   -   EUCTR2004-004051-19-IT   Germany;Italy;Sweden;United Kingdom
   Bristol-Myers Squibb
      2020   Phase 2   NCT04186871   Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2007   Phase 2/Phase 3   NCT00430677   Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States
      2005   Phase 2   NCT00119678   Australia;Austria;Belgium;Brazil;Canada;France;Germany;Italy;Korea, Republic of;Mexico;Puerto Rico;South Africa;Sweden;Taiwan;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2008   Phase 2;Phase 3   EUCTR2005-004575-37-GB   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-FR   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-BE   Belgium;France;United Kingdom
      2005   -   EUCTR2004-004051-19-SE   Germany;Italy;Sweden;United Kingdom
      2005   -   EUCTR2004-004051-19-GB   Germany;Italy;Sweden;United Kingdom
      2005   -   EUCTR2004-004051-19-DE   Germany;Italy;Sweden;United Kingdom
      2005   -   EUCTR2004-004051-19-BE   Austria;Belgium;Germany;Italy;Sweden;United Kingdom
      2005   -   EUCTR2004-004051-19-AT   Austria;Germany;Italy;Sweden;United Kingdom
   Oklahoma Medical Research Foundation
      2014   Phase 2   NCT02270957   United States
Abatacept also known AS orencia also known AS CTLA4-IG
   University of California, Los Angeles
      2015   Phase 1/Phase 2   NCT02429934   United States
ABBV-105
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 2   EUCTR2020-001690-72-IT   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000638-20-IT   Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
   AbbVie Deutschland GmbH & Co. KG
      2021   Phase 2   EUCTR2020-001690-72-DE   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001690-72-BG   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001690-72-NL   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001690-72-HU   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000638-20-NL   Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000638-20-DE   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000638-20-BG   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000638-20-HU   Argentina;Australia;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000638-20-ES   Argentina;Australia;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
   Yamazaki Hayato
      2021   Phase 2   JPRN-jRCT2031210119   Argentina;Bulgaria;China;Germany;Hungary;Japan;Mexico;Netherlands;Poland;Puerto Rico;Spain;Taiwan;United States
ABBV-319
   AbbVie
      2025   Phase 1   NCT06977724   -
Abetimus sodium
   AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
      2009   -   EUCTR2008-004852-62-IT   Italy
   LA JOLLA PHARMACEUTICAL COMPANY
      2008   -   EUCTR2006-000674-73-IT   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
   La Jolla Pharmaceutical Company
      2008   -   EUCTR2006-000674-73-PT   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
      2008   -   EUCTR2006-000674-73-ES   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
      2008   -   EUCTR2006-000674-73-DE   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
      2008   -   EUCTR2006-000674-73-CZ   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
      2008   -   EUCTR2006-000674-73-BG   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
      2006   Phase 2   NCT00390091   United States
      2006   Phase 3   EUCTR2006-000674-73-SK   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Slovakia;Spain
      2006   -   EUCTR2006-000674-73-HU   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
      2004   Phase 3   NCT00089804   Argentina;Australia;Belarus;Brazil;Bulgaria;Czech Republic;Former Serbia and Montenegro;Georgia;Germany;Hong Kong;Hungary;India;Indonesia;Italy;Korea, Republic of;Lebanon;Malaysia;Mexico;Philippines;Poland;Portugal;Puerto Rico;Romania;Serbia;Slovakia;Spain;Sri Lanka;Taiwan;Thailand;Ukraine;United States
      2001   Phase 3   NCT00035308   Austria;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
ABR-215757
   Active Biotech AB
      2009   Phase 2   NCT00997100   Denmark;Sweden
   Active Biotech Research AB
      2009   -   EUCTR2009-011245-55-SE   Denmark;Sweden
      2009   -   EUCTR2009-011245-55-DK   Denmark;Sweden
ABT-199
   AbbVie (prior sponsor, Abbott)
      2012   Phase 1   NCT01686555   Germany;Mexico;Puerto Rico;United States
ABT-494
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 2   EUCTR2020-001690-72-IT   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000638-20-IT   Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
   AbbVie Deutschland GmbH & Co. KG
      2021   Phase 2   EUCTR2020-001690-72-DE   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001690-72-BG   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001690-72-NL   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001690-72-HU   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000638-20-NL   Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000638-20-DE   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000638-20-BG   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000638-20-HU   Argentina;Australia;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000638-20-ES   Argentina;Australia;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
   Yamazaki Hayato
      2021   Phase 2   JPRN-jRCT2031210119   Argentina;Bulgaria;China;Germany;Hungary;Japan;Mexico;Netherlands;Poland;Puerto Rico;Spain;Taiwan;United States
AC0058TA
   ACEA Therapeutics, Inc.
      2018   Phase 1   NCT03878303   United States
Acazicolcept
   Alpine Immune Sciences, Inc.
      2022   Phase 2   EUCTR2020-004047-86-HU   France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2020-004047-86-PL   France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2020-004047-86-ES   France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;United States
      -   Phase 2   EUCTR2020-004047-86-FR   France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;United States
Acetaminophen
   Genentech, Inc.
      2006   Phase 3   NCT00381810   United States
      2005   Phase 2/Phase 3   NCT00137969   Canada;United States
Acetaminophen/paracetamol
   Hoffmann-La Roche
      2021   Phase 3   NCT04963296   Argentina;Brazil;Czechia;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
Acetate
   Bristol-Myers Squibb
      2017   Phase 1   NCT03262727   United States
   Guang'anmen Hospital, China Academy of Chinese Medical Sciences
      2023   Phase 1   ChiCTR2300073848   China
Acido micofenolico
   Manuel Praga Terente
      2010   -   EUCTR2009-017273-38-ES   Spain
ACM
   Manuel Praga Terente
      2010   -   EUCTR2009-017273-38-ES   Spain
ACT-334441
   ACTELION Pharmaceuticals Ltd
      2015   Phase 2   EUCTR2014-002984-14-BG   Belarus;Bulgaria;Georgia;Russian Federation;Ukraine;United States
   IDORSIA PHARMACEUTICALS LTD
      2019   Phase 2   EUCTR2018-001808-11-IT   Bulgaria;Chile;China;Colombia;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
   Idorsia Pharmaceuticals Ltd
      2023   Phase 3   EUCTR2022-002815-47-PT   Chile;China;Czech Republic;Czechia;Georgia;Germany;Japan;Mexico;Peru;Philippines;Poland;Portugal;Serbia;South Africa;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002815-47-DE   Chile;China;Czech Republic;Czechia;Georgia;Germany;Japan;Mexico;Peru;Philippines;Poland;Portugal;Serbia;South Africa;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002815-47-CZ   Chile;China;Czech Republic;Czechia;Georgia;Germany;Japan;Mexico;Peru;Philippines;Poland;Portugal;Serbia;South Africa;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002814-17-RO   Argentina;Brazil;Bulgaria;China;Colombia;France;Greece;Korea, Republic of;Malaysia;Mexico;Philippines;Poland;Romania;Taiwan;Thailand;United States
      2023   Phase 3   EUCTR2022-002814-17-GR   Argentina;Brazil;Bulgaria;China;Colombia;France;Greece;Korea, Republic of;Malaysia;Mexico;Philippines;Poland;Romania;Taiwan;Thailand;United States
      2023   Phase 3   EUCTR2022-002814-17-FR   Argentina;Brazil;Bulgaria;China;Colombia;France;Greece;Korea, Republic of;Malaysia;Mexico;Philippines;Poland;Romania;Taiwan;Thailand;United States
      2023   Phase 3   EUCTR2022-002814-17-BG   Argentina;Brazil;Bulgaria;China;Colombia;France;Greece;Korea, Republic of;Malaysia;Mexico;Philippines;Poland;Romania;Taiwan;Thailand;United States
      2020   Phase 2   EUCTR2018-001808-11-GR   Bulgaria;Chile;China;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001808-11-PL   Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001808-11-HU   Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001808-11-FR   Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001808-11-ES   Bulgaria;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001808-11-DE   Bulgaria;China;Czech Republic;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001808-11-BG   Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 2   EUCTR2018-001808-11-GB   Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
   Yokoyama Yoshinari
      2023   Phase 3   JPRN-jRCT2051230027   Africa region;Asia-Pacific region;European region;Japan;North Central South America;United States
Acthar
   Mallinckrodt
      2013   Phase 4   NCT01753401   United States
   NYU Langone Health
      2016   Phase 4   NCT02779153   United States
Acthar GEL
   Mallinckrodt
      2016   Phase 4   NCT02953821   Argentina;Chile;Colombia;Mexico;Peru;United States
AD26.COV2.S
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
ADI-001
   Adicet Therapeutics
      2024   Phase 1   NCT06375993   United States
Administration OF methylprednisolone + prednisone + mycophenolate mofetil
   Assistance Publique - Hôpitaux de Paris
      2021   Phase 3   NCT04702256   France
Administration OF methylprednisolone, paracetamol and dexchlorpheniramine
   Assistance Publique - Hôpitaux de Paris
      2021   Phase 3   NCT04702256   France
Aerobic exercises
   Cairo University
      2022   -   NCT05392790   Egypt
Afimetoran
   Bristol-Myers Squibb
      2021   Phase 2   NCT04895696   Argentina;Australia;Brazil;Chile;China;Colombia;France;Germany;India;Ireland;Japan;Mexico;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2022   Phase 2   EUCTR2019-004021-25-RO   Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2019-004021-25-PL   Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2019-004021-25-IE   Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States
   Ranganathan Usha
      2022   Phase 2   JPRN-jRCT2011210069   Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;USA;United Kingdom
AGS-009
   Argos Therapeutics
      2009   Phase 1   NCT00960362   Sweden;United States
Aidsvax® B/E
   National Institute of Allergy and Infectious Diseases (NIAID)
      2018   Phase 1   NCT03618056   United States
AKBM-3031
   Aker Biomarine Antarctic AS
      2018   -   NCT03626311   Canada;United States
Aldesleuchina
   ILTOO PHARMA
      2017   Phase 2   EUCTR2016-000488-17-IT   Austria;Bulgaria;France;Italy;Portugal;Spain
Aldesleukin
   Charité - Universitätsmedizin Berlin
      2014   Phase 1;Phase 2   EUCTR2013-001599-40-DE   Germany
   ILTOO PHARMA
      2018   Phase 2   EUCTR2016-000488-17-FR   Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain
      2017   Phase 2   EUCTR2016-000488-17-BG   Austria;Bulgaria;France;Germany;Italy;Mexico;Portugal;Romania;Spain
      2016   Phase 2   EUCTR2016-000488-17-PT   Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain
      2016   Phase 2   EUCTR2016-000488-17-ES   Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain
      2016   Phase 2   EUCTR2016-000488-17-AT   Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain
   Onur Boyman, MD
      2018   Phase 2   NCT03312335   Switzerland
Alitretinoin
   Universitätsklinikum Münster
      2011   -   EUCTR2010-024131-16-DE   Germany
Allogeneic bone marrow transplant
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 1/Phase 2   NCT02080195   United States
Allogeneic mesenchymal stromal cells derived from THE umbilical cord
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2018   Phase 1;Phase 2   EUCTR2017-001400-29-FR   France
Allogeneic stem cell transplantation
   Northwestern University
      2004   Phase 1   NCT00278590   United States
Alpha-tocopherol
   GreenPark Healthcare Trust
      2004   Phase 4   EUCTR2004-004404-21-GB   United Kingdom
ALPN-101
   Alpine Immune Sciences, Inc.
      2022   Phase 2   EUCTR2020-004047-86-HU   France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States
      2021   Phase 2   NCT04835441   France;Hungary;Korea, Republic of;Poland;Puerto Rico;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2020-004047-86-PL   France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2020-004047-86-ES   France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;United States
      -   Phase 2   EUCTR2020-004047-86-FR   France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;United States
ALX-0061
   Ablynx
      2015   Phase 2   NCT02437890   Argentina;Chile;Czech Republic;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
ALX-0061 150 MG/ML
   Ablynx N.V.
      2015   Phase 2   EUCTR2015-000372-95-PT   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2015   Phase 2   EUCTR2015-000372-95-HU   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2015   Phase 2   EUCTR2015-000372-95-ES   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2015   Phase 2   EUCTR2015-000372-95-DE   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2015   Phase 2   EUCTR2015-000372-95-CZ   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
AMG 557
   Amgen
      2012   Phase 1   NCT01683695   Australia;Denmark;France;Germany;Malaysia;Singapore;Taiwan;United Kingdom;United States
      2008   Phase 1   NCT00774943   Canada;United States
      2006   Phase 1   NCT02391259   United Kingdom;United States
AMG 570
   AMGEN INC.
      2019   Phase 2   EUCTR2019-000328-16-IT   Australia;Austria;Bulgaria;Canada;Czechia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States
   Amgen
      2016   Phase 1   NCT02618967   United States
   Amgen Inc
      2021   Phase 2   EUCTR2019-000328-16-GR   Argentina;Australia;Bulgaria;Canada;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000328-16-PT   Australia;Austria;Bulgaria;Canada;Czechia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000328-16-HU   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000328-16-FR   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000328-16-DE   Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States
AMG 592
   AMGEN INC.
      2021   Phase 2   EUCTR2020-003509-72-IT   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
   Amgen Inc
      2018   Phase 1;Phase 2   EUCTR2017-002564-40-DE   France;Germany;Poland;United States
   Amgen Inc.
      2021   Phase 2   EUCTR2020-003509-72-PL   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-GR   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-FR   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-ES   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-BG   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-AT   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United States
AMG 623
   Amgen
      2005   Phase 1   NCT02411136   -
      2004   Phase 1   NCT02443506   -
AMG 811
   Amgen
      2009   Phase 1   NCT00818948   France;Hong Kong;Malaysia;Mexico;Singapore;United States
      2007   Phase 1   NCT02291588   -
AMG592
   Amgen Inc
      2018   Phase 1;Phase 2   EUCTR2017-002564-40-DE   France;Germany;Poland;United States
AMG811
   Amgen
      2010   Phase 1   NCT01164917   United States
Anakinra
   Dr Josep Ordi Ros
      2012   Phase 2   EUCTR2011-005392-16-ES   Spain
Angiotensin converting enzyme test
   Sohag University
      2023   -   NCT05516511   Egypt
Anifrolumab
   ASTRAZENECA AB
      2015   Phase 3   EUCTR2014-004633-96-IT   Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States
   AstraZeneca
      2025   -   NCT06795893   -
      2025   -   NCT06673043   Poland
      2025   -   NCT06659029   United States
      2025   Phase 4   NCT06594068   United States
      2024   Phase 3   NCT05835310   Argentina;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Mexico;Poland;Portugal;South Africa;Spain;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004529-22-DE   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Thailand;Ukraine;United Kingdom;United States
      2021   Phase 3   NCT04931563   China;Hong Kong;Korea, Republic of;Philippines;Taiwan;Thailand
      2021   -   NCT04750057   -
      2021   Phase 3   EUCTR2020-004529-22-HU   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Thailand;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004529-22-BG   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Thailand;Ukraine;United Kingdom;United States
      2017   Phase 2   NCT02962960   Hungary;Korea, Republic of;Poland;United States
      2017   Phase 3   JPRN-jRCT2080223489   Asia except Japan;Europe;Japan;North America;Oceania;South America
      2016   Phase 3   NCT02794285   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2016   Phase 3   JPRN-jRCT2080223010   Africa;Asia except Japan;Europe;Japan;North America;South America
      2015   Phase 3   NCT02446912   Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States
      2015   Phase 3   NCT02446899   Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Japan;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States
   AstraZeneca AB
      2017   Phase 3   EUCTR2016-000625-39-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000625-39-LT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000625-39-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000625-39-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000625-39-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-004633-96-RO   Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-004633-96-PL   Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-004633-96-HU   Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-004633-96-GB   Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-004633-96-DE   Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-004632-19-LT   Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States
      2015   Phase 3   EUCTR2014-004632-19-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States
      2015   Phase 3   EUCTR2014-004632-19-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;United States
      2015   Phase 3   EUCTR2014-004632-19-CZ   Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States
      2015   Phase 3   EUCTR2014-004632-19-BG   Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States
      2015   Phase 3   EUCTR2014-004632-19-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States
   Astrazeneca AB
      2017   Phase 2   EUCTR2016-003246-93-PL   Hungary;Korea, Republic of;Poland;United States
      2016   Phase 2   EUCTR2016-003246-93-HU   Hungary;Korea, Republic of;Poland;United States
   Hibi Kazushige
      2022   Phase 3   JPRN-jRCT2071210076   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Mexico;Peru;Poland;Russia;Spain;Ukraine;United Kingdom;United States
   MedImmune LLC
      2013   Phase 2   NCT01753193   Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States
   MedImmune, LLC, a wholly owned subsidiary of AstraZeneca
      2014   Phase 2   EUCTR2012-004619-30-BG   Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States
      2013   Phase 2   EUCTR2012-004619-30-HU   Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States
      2013   Phase 2   EUCTR2012-004619-30-CZ   Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States
   NHS Greater Glasgow and Clyde
      2025   -   NCT06784076   -
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2023   Phase 2   NCT05440422   United States
   Oklahoma Medical Research Foundation
      2021   Early Phase 1   NCT04726553   United States
Anifrolumab 1000 MG
   MedImmune LLC
      2012   Phase 2   NCT01438489   Brazil;Bulgaria;Colombia;Czech Republic;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States
Anifrolumab 300 MG
   MedImmune LLC
      2012   Phase 2   NCT01438489   Brazil;Bulgaria;Colombia;Czech Republic;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States
   Tsuboi Hiroto
      2023   -   JPRN-jRCTs031230358   -
Anti LP40 antibody, subclass IGG4
   Eli Lilly and Company
      2014   -   EUCTR2010-022101-18-HR   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2013   -   EUCTR2010-022101-18-DE   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-LV   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-HU   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-GB   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-ES   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-BG   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-AT   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2010-022100-42-LV   Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States
      2011   -   EUCTR2010-022100-42-HU   Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States
      2011   Phase 3   EUCTR2010-022100-42-GB   Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States
      2011   -   EUCTR2010-022099-29-DE   Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States
      2011   -   EUCTR2010-022099-29-BG   Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States
      2011   -   EUCTR2010-022099-29-AT   Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States
Anti LP40 anticuerpo, subclase IGG4
   Eli Lilly and Company
      2011   -   EUCTR2010-022100-42-ES   Hungary;Latvia;Spain;United Kingdom
Anti phospholipid marker
   Sohag University
      2024   -   NCT06294483   Egypt
ANTI-bcma/CD70-CAR-T cells
   The Children's Hospital of Zhejiang University School of Medicine
      2025   Phase 1   NCT06934447   China
ANTI-blood dendritic cell antigen 2
   Biogen Idec Research Limited
      2017   Phase 2   EUCTR2015-004359-32-PL   Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States
      2017   Phase 2   EUCTR2015-004359-32-BG   Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States
ANTI-CD19 CAR T cell therapy
   University of Erlangen-Nürnberg Medical School
      2023   Phase 1/Phase 2   NCT06347718   Germany
ANTI-CD19 CAR-NK cells
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2024   Phase 1   NCT06421701   China
ANTI-CD19-CAR-T cells
   First Affiliated Hospital of Wenzhou Medical University
      2024   Early Phase 1   NCT06420154   China
   Shanghai GeneChem Co., Ltd.
      2017   Phase 1   NCT03030976   China
   The Children's Hospital of Zhejiang University School of Medicine
      2024   Phase 1   NCT06222853   China
ANTI-CD19-CD3E-CAR-T cells
   Shanghai Changzheng Hospital
      2024   -   NCT06373081   China
ANTI-CD20 B cell depletion with truxima
   Leiden University Medical Center
      2018   Phase 2;Phase 3   EUCTR2018-001392-21-NL   Netherlands
ANTI-CD28DAB
   Bristol-Myers Squibb International Corporation
      2015   Phase 2   EUCTR2014-002184-14-NL   Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-002184-14-IT   Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-002184-14-HU   Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-002184-14-DE   Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States
      2014   Phase 2   EUCTR2014-002184-14-ES   Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States
ANTI-macrophage migration inhibitory factor (ANTI-MIF) antibody
   Baxalta now part of Shire
      2011   Phase 1   NCT01541670   Australia;Canada;Mexico;New Zealand;United States
ANTI-pandemic H1n1 influenza vaccine
   University of Sao Paulo
      2010   Phase 4   NCT01151644   Brazil
ANTI-thymocyte globulin
   Fairview University Medical Center
      2000   -   NCT00006055   United States
   Northwestern Memorial Hospital
      2001   Phase 1   NCT00017641   United States
APG-2575
   Ascentage Pharma Group Inc.
      2024   Phase 1/Phase 2   NCT06182969   China
Aspirin
   Brigham and Women's Hospital
      2003   Phase 2   NCT00054938   United States
   Tuen Mun Hospital
      2006   Phase 4   NCT00371501   Hong Kong
Aspirin and meloxicam
   Vanderbilt University
      2005   Phase 1   NCT00731302   United States
Assigned interventions CD19/bcma CAR T-cells
   Zhejiang University
      2021   Early Phase 1   NCT05030779   China
ATA3219
   Atara Biotherapeutics
      2025   Phase 1   NCT06429800   United States
Atacicept
   EMD Serono
      2012   Phase 2   NCT01440231   United States
   Merck KGaA
      2014   Phase 2   EUCTR2013-002773-21-IT   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002773-21-GB   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002773-21-ES   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002773-21-DE   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002773-21-CZ   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002758-62-IT   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002758-62-GB   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002758-62-ES   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002758-62-DE   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002758-62-CZ   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002758-62-BG   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
   Merck Serono International
      2008   -   EUCTR2007-003698-13-BG   Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom
   Merck Serono International SA, An affiliate of Merck KGaA, Darmstadt, Germany
      2008   Phase 2;Phase 3   EUCTR2007-003698-13-FR   Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom
      2008   Phase 2;Phase 3   EUCTR2007-003698-13-ES   Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom
   Merck Serono S.A. Geneva. An affiliate of Merck KGaA, Darmstadt, Germany
      2008   -   EUCTR2007-003698-13-NL   Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States
      2008   -   EUCTR2007-003698-13-LV   Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-003698-13-LT   Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States
      2008   -   EUCTR2007-003698-13-GR   Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom
      2008   Phase 2;Phase 3   EUCTR2007-003698-13-GB   Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States
      2008   -   EUCTR2007-003698-13-CZ   Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Spain;Taiwan;United Kingdom;United States
      -   -   EUCTR2007-003698-13-DE   Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States
   Merck Serono SA - Geneva
      2008   -   EUCTR2007-003698-13-AT   Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom
Atacicept 150 MG
   EMD Serono
      2014   Phase 2   NCT02070978   Argentina;Brazil;Bulgaria;Chile;Czechia;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
      2013   Phase 2   NCT01972568   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Czechia;Germany;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2008   Phase 2/Phase 3   NCT00624338   Argentina;Australia;Austria;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States
Atacicept 75 MG
   EMD Serono
      2014   Phase 2   NCT02070978   Argentina;Brazil;Bulgaria;Chile;Czechia;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
      2008   Phase 2/Phase 3   NCT00624338   Argentina;Australia;Austria;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States
Athena CAR-T
   EdiGene Inc.
      2024   Phase 1   NCT06373991   China
Atorvastatin
   Buddhist Tzu Chi General Hospital
      2007   Phase 2/Phase 3   NCT00432354   Taiwan
   Johns Hopkins University
      2002   Phase 4   NCT00120887   United States
   NYU Langone Health
      2002   Phase 2   NCT00412841   United States
   The Center for Rheumatic Disease, Allergy, & Immunology
      2007   Phase 1/Phase 2   NCT00519363   United States
   The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
      2017   -   ChiCTR-INC-17011497   China
Autologous EBV specific CTL infusion
   Nantes University Hospital
      2016   Phase 1/Phase 2   NCT02677688   France
Autologous hematopoietic stem cell transplantation
   European Society for Blood and Marrow Transplantation
      2009   Phase 2/Phase 3   NCT05063513   France
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00076752   United States
Autologous peripheral blood stem cell transplantation
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Aviptadil
   MONDOGEN AG
      2008   -   EUCTR2007-003621-24-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
   MondoGEN AG
      2009   -   EUCTR2007-003621-24-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-003621-24-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-003621-24-GB   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-003621-24-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-003621-24-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-003621-24-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
Azathioprine
   Chinese SLE Treatment And Research Group
      2015   Phase 3   NCT02444728   China
   Department of Rheumatology, Internal Medicine III, Medical University of Vienna
      2006   -   EUCTR2005-004067-30-NL   Austria;Germany;Netherlands
      2006   -   EUCTR2005-004067-30-DE   Austria;Germany;Netherlands
      2006   -   EUCTR2005-004067-30-AT   Austria;Germany;Netherlands
   Genentech, Inc.
      2007   Phase 3   NCT00539838   United States
   Hospital Universitari Vall d'Hebron Research Institute
      2009   Phase 4   NCT01112215   Spain
   ISTITUTO GIANNINA GASLINI
      2006   Phase 3   EUCTR2005-003957-28-IT   Belgium;Denmark;Italy
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00230035   United States
   University Hospital Gent
      -   Phase 3   EUCTR2005-003957-28-BE   Belgium;Denmark;Italy
   Zhejiang Chinese Medical University
      2021   -   ChiCTR2100048796   China
      2015   -   ChiCTR-ONC-15007547   China
AZD0120
   AstraZeneca
      2025   Phase 1/Phase 2   NCT06897930   United States
AZD5492
   AstraZeneca
      2025   Phase 1   NCT06916806   Canada;China;France;Germany;Japan;Netherlands;Spain;United Kingdom;United States
Balanced diet
   Chang Gung Memorial Hospital
      2022   -   NCT05689580   Taiwan
Baricinitib
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2018   Phase 3   EUCTR2017-005027-25-IT   Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States
Baricitinib
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 3   EUCTR2017-005028-11-IT   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005027-25-IT   Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States
   Eli Lilly Japan K.K.
      2018   Phase 3   JPRN-jRCT2080224034   Africa;Asia except Japan;Europe;Japan;North America;South America
      2016   Phase 2   JPRN-jRCT2080223304   -
   Eli Lilly and Company
      2020   Phase 3   EUCTR2017-005028-11-NL   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2017-005028-11-HR   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2017-005028-11-GR   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   NCT03843125   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-RO   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-PL   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-HU   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-GB   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Czech Republic;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-ES   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-DE   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-CZ   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-AT   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005027-25-PL   Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States
      2019   Phase 3   EUCTR2017-005026-37-NL   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Czechia;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005026-37-HR   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005026-37-GR   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005026-37-GB   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   NCT03616964   Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States
      2018   Phase 3   NCT03616912   Australia;Austria;Belgium;Brazil;China;Croatia;Czechia;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005027-25-ES   Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States
      2018   Phase 3   EUCTR2017-005026-37-HU   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005026-37-CZ   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005026-37-BE   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005026-37-AT   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Czechia;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2016   Phase 2   NCT02708095   Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Romania;Spain;Taiwan;United States
      2016   Phase 2   EUCTR2015-004404-35-RO   Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United States
      2016   Phase 2   EUCTR2015-004404-35-PL   Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004404-35-FR   Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004404-35-AT   Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United States
   Lilly S.A.
      2016   Phase 2   EUCTR2015-004404-35-ES   Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United States
BCMA-CD19 CAR-T therapy
   Peking University People's Hospital
      2024   Phase 2   NCT06794008   China
Bcma/CD19 CAR-T cells
   Essen Biotech
      2024   Phase 1/Phase 2   NCT06428188   China
Belimumab
   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
      2023   -   NCT06327724   Netherlands
   Affiliated Hospital of Guilin Medical College
      2021   Phase 4   ChiCTR2100052342   China
      2021   Phase 4   ChiCTR2100043138   China
   Biomedical Research Foundation, Academy of Athens
      2020   -   NCT04570306   Greece
   First Affiliated Hospital Xi'an Jiaotong University
      2024   Phase 4   NCT04893161   -
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2013   -   EUCTR2011-000368-88-IT   Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Spain;United Kingdom;United States
   GlaxoSmithKline
      2024   Phase 1   NCT06576271   United Kingdom
      2024   Phase 4   NCT06411249   Argentina;Brazil;France;Germany;Greece;Italy;Japan;Mexico;Portugal;Spain;United States
      2023   Phase 1   NCT05917288   China
      2021   Phase 4   NCT04908865   China
      2019   Phase 2   NCT04179032   Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States
      2018   Phase 3   NCT03312907   Argentina;Brazil;Canada;France;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States
      2017   Phase 1   NCT02880852   China
      2015   -   NCT01532310   Argentina;Austria;Belgium;Canada;France;Germany;Israel;Italy;Portugal;Spain;Sweden;Switzerland;United States
      2014   Phase 3   NCT02119156   China;Japan;Korea, Republic of;United States
      2012   Phase 3   NCT01597622   Japan;Korea, Republic of
      2011   Phase 3   NCT01345253   China;Japan;Korea, Republic of
   GlaxoSmithKline K.K.
      2019   Phase 2   JPRN-jRCT2080224941   Argentina;Germany;Mexico;Netherlands;Spain;United States
   GlaxoSmithKline Research & Development Limited
      -   Phase 1   EUCTR2025-000142-26-Outside-EU/EEA   China
      -   Phase 4   EUCTR2025-000106-42-Outside-EU/EEA   China
   GlaxoSmithKline Research & Development Ltd
      2020   Phase 2   EUCTR2018-004645-16-NL   Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States
      2019   Phase 2   EUCTR2018-004645-16-DE   Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States
      2018   Phase 3   EUCTR2016-003050-32-NL   Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States
      2018   Phase 3   EUCTR2016-003050-32-DE   Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States
      2012   -   EUCTR2011-000368-88-NL   Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2012   Phase 2   EUCTR2011-000368-88-GB   Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2011-000368-88-PL   Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      -   -   EUCTR2011-000368-88-Outside-EU/EEA   Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
   GlaxoSmithKline, LLC
      2013   Phase 4   EUCTR2011-005667-25-PT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-LT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-CZ   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
   GlaxoSmithKline, S.A.
      2019   Phase 2   EUCTR2018-004645-16-ES   Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States
      2017   Phase 3   EUCTR2016-003050-32-ES   Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;South Africa;Spain;United States
      2012   -   EUCTR2011-000368-88-ES   Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
   Guangzhou Women's and Children's Medical Center
      2021   -   ChiCTR2100050041   China
   HUMAN GENOME SCIENCES INC
      2013   Phase 4   EUCTR2011-005667-25-IT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;European Union;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2012   -   EUCTR2011-003814-18-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2009   Phase 3   EUCTR2007-007648-85-IT   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-IT   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
   Human Genome Sciences Inc.
      2002   Phase 1   NCT00657007   United States
   Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
      2014   Phase 4   EUCTR2011-005667-25-PL   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-SK   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-RO   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-ES   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-EE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2012   Phase 3   EUCTR2011-003814-18-SE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003814-18-DK   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   -   EUCTR2011-003814-18-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
   Human Genome Sciences Inc., a GSK Company
      2008   Phase 3   NCT00712933   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Costa Rica;Czech Republic;Czechia;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;United Kingdom
      2005   Phase 2   NCT00583362   Canada;United States
   Human Genome Sciences, Inc
      2009   Phase 3   EUCTR2007-007648-85-SK   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
   Human Genome Sciences, Inc.
      2012   -   EUCTR2011-003814-18-ES   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   -   EUCTR2011-003814-18-CZ   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2010   Phase 3   EUCTR2007-007648-85-AT   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
      2009   Phase 1;Phase 3   EUCTR2007-007648-85-SE   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
      2009   Phase 3   EUCTR2007-007648-85-GB   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
      2009   Phase 3   EUCTR2007-007648-85-FR   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-007648-85-ES   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-007648-85-DE   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom
      2009   Phase 3   EUCTR2007-007648-85-BE   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
      2007   Phase 3   EUCTR2006-005177-21-SK   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-SE   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-NL   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005177-21-GB   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005177-21-FR   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005177-21-ES   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-DE   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-CZ   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-BE   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-AT   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
   Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
      2013   Phase 3;Phase 4   EUCTR2011-005672-42-GB   Brazil;Colombia;France;Martinique;South Africa;United Kingdom;United States
      2012   -   EUCTR2011-003814-18-HU   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   -   EUCTR2011-003814-18-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003814-18-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003814-18-BE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2009   Phase 3   EUCTR2007-007648-85-NL   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
      2009   Phase 3   EUCTR2007-007648-85-CZ   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
   Human Genome Sciences, Inc. (a wholy owned subsidiary of GlaxoSmithKline PLC)
      2012   Phase 3   EUCTR2011-003814-18-GB   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
   Human Genome Sciences, a wholly owned subsidiary of GlaxoSmithKline, Plc
      2012   Phase 3   EUCTR2011-003814-18-PT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   -   EUCTR2011-003814-18-PL   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
   Ishii Tomonori
      2022   -   JPRN-jRCTs021210042   -
   Leiden University Medical Center
      2014   Phase 2   EUCTR2014-000488-42-NL   Netherlands
   Oklahoma Medical Research Foundation
      2014   Phase 4   NCT02270970   United States
   Peking University People's Hospital
      2022   Phase 3   NCT05262686   China
   RenJi Hospital
      2021   Phase 4   NCT04515719   China
   The Second Hospital of Shanxi Medical University
      2021   -   ChiCTR2200055471   China
   University College London
      2016   Phase 2   EUCTR2015-005543-14-GB   United Kingdom
   Xi'an Jiaotong University
      2022   Phase 4   ChiCTR2200066022   China
Belimumab 1 MG/KG
   GlaxoSmithKline
      2009   -   NCT01914770   -
   Human Genome Sciences Inc.
      2007   Phase 3   NCT00424476   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Hong Kong;India;Korea, Republic of;Peru;Philippines;Romania;Russian Federation;Taiwan
      2006   Phase 3   NCT00410384   Austria;Belgium;Canada;Costa Rica;Czech Republic;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States
      2003   Phase 2   NCT00071487   Canada;United States
   Human Genome Sciences Inc., a GSK Company
      2011   -   NCT01858792   -
      2008   Phase 3   NCT00724867   Canada;United States
Belimumab 10 MG/KG
   GlaxoSmithKline
      2009   -   NCT01914770   -
   Human Genome Sciences Inc.
      2007   Phase 3   NCT00424476   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Hong Kong;India;Korea, Republic of;Peru;Philippines;Romania;Russian Federation;Taiwan
      2006   Phase 3   NCT00410384   Austria;Belgium;Canada;Costa Rica;Czech Republic;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States
      2003   Phase 2   NCT00071487   Canada;United States
   Human Genome Sciences Inc., a GSK Company
      2011   -   NCT01858792   -
      2008   Phase 3   NCT00724867   Canada;United States
Belimumab 10 MG/KG plus standard therapy
   GlaxoSmithKline
      2012   Phase 4   NCT01705977   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;Indonesia;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Ukraine;United States
   Human Genome Sciences Inc., a GSK Company
      2013   Phase 4   NCT01632241   Brazil;Colombia;France;South Africa;United Kingdom;United States
Belimumab 100 MG SC
   Human Genome Sciences Inc.
      2008   Phase 2   NCT00732940   Mexico;United States
Belimumab 10MG/KG
   GlaxoSmithKline
      2012   Phase 2   NCT01649765   Argentina;Brazil;Canada;Italy;Japan;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
Belimumab 200 MG SC
   Human Genome Sciences Inc., a GSK Company
      2011   Phase 3   NCT01484496   Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Malaysia;Mexico;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
Belimumab 200 MG/ML
   GlaxoSmithKline
      2013   Phase 1   NCT01894360   United States
Belimumab 4 MG/KG
   Human Genome Sciences Inc.
      2003   Phase 2   NCT00071487   Canada;United States
Belimumab autoinjector
   GlaxoSmithKline
      2014   Phase 2   NCT02124798   United States
Belimumab FOR IV
   GlaxoSmithKline
      2019   Phase 1   NCT04136145   China
Belimumab FOR SC
   GlaxoSmithKline
      2019   Phase 1   NCT04136145   China
Belimumab IN SLE patients / rituximab IN RA patients
   University of Cagliari
      2020   -   NCT05659407   Italy
Belimumab injection
   Leiden University Medical Center
      2018   Phase 3   NCT03747159   Netherlands
   National University Hospital, Singapore
      2021   Phase 4   NCT04447053   Singapore
Belimumab or benlysta
   Leiden University Medical Center
      2018   Phase 2;Phase 3   EUCTR2018-001392-21-NL   Netherlands
Belimumab plus early vaccination
   Human Genome Sciences Inc., a GSK Company
      2012   Phase 4   NCT01597492   United States
Belimumab plus late vaccination
   Human Genome Sciences Inc., a GSK Company
      2012   Phase 4   NCT01597492   United States
Benazepril pill
   Northwell Health
      2021   Phase 2   NCT04486118   United States
Bendamustine
   Fate Therapeutics
      2024   Phase 1   NCT06308978   United States
Benlysta
   Fraunhofer Institut für Translationale Medizin und Pharmakologie (ITMP)
      2021   Phase 4   EUCTR2021-001802-30-DE   Germany
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2013   -   EUCTR2011-000368-88-IT   Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Spain;United Kingdom;United States
   GlaxoSmithKline
      2018   -   NCT03370263   Japan
      2013   -   NCT01729455   Argentina;Austria;Belgium;Canada;France;Germany;Israel;Italy;Portugal;Slovakia;Spain;Sweden;United States
   GlaxoSmithKline Research & Development Limited
      -   Phase 1   EUCTR2025-000142-26-Outside-EU/EEA   China
      -   Phase 4   EUCTR2025-000106-42-Outside-EU/EEA   China
   GlaxoSmithKline Research & Development Ltd
      2020   Phase 2   EUCTR2018-004645-16-NL   Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States
      2019   Phase 2   EUCTR2018-004645-16-DE   Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States
      2012   -   EUCTR2011-000368-88-NL   Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2012   Phase 2   EUCTR2011-000368-88-GB   Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2011-000368-88-PL   Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      -   -   EUCTR2011-000368-88-Outside-EU/EEA   Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
   GlaxoSmithKline, S.A.
      2019   Phase 2   EUCTR2018-004645-16-ES   Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States
      2012   -   EUCTR2011-000368-88-ES   Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
   HUMAN GENOME SCIENCES INC
      2012   -   EUCTR2011-003814-18-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
   Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
      2012   Phase 3   EUCTR2011-003814-18-SE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003814-18-DK   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   -   EUCTR2011-003814-18-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
   Human Genome Sciences, Inc.
      2012   -   EUCTR2011-003814-18-ES   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   -   EUCTR2011-003814-18-CZ   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
   Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
      2012   -   EUCTR2011-003814-18-HU   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   -   EUCTR2011-003814-18-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003814-18-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003814-18-BE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2009   Phase 3   EUCTR2007-007648-85-CZ   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
   Human Genome Sciences, Inc. (a wholy owned subsidiary of GlaxoSmithKline PLC)
      2012   Phase 3   EUCTR2011-003814-18-GB   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
   Human Genome Sciences, a wholly owned subsidiary of GlaxoSmithKline, Plc
      2012   Phase 3   EUCTR2011-003814-18-PT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   -   EUCTR2011-003814-18-PL   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
   Ishii Tomonori
      2022   -   JPRN-jRCTs021210042   -
   Leiden University Medical Center
      2014   Phase 2   EUCTR2014-000488-42-NL   Netherlands
   National University Hospital, Singapore
      2021   Phase 4   NCT04447053   Singapore
Benlysta 400 MG powder FOR concentrate FOR solution FOR infusion
   GlaxoSmithKline, LLC
      2013   Phase 4   EUCTR2011-005667-25-PT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-LT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-CZ   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
   HUMAN GENOME SCIENCES INC
      2013   Phase 4   EUCTR2011-005667-25-IT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;European Union;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
   Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
      2014   Phase 4   EUCTR2011-005667-25-PL   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-SK   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-RO   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-ES   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-EE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
   Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
      2013   Phase 3;Phase 4   EUCTR2011-005672-42-GB   Brazil;Colombia;France;Martinique;South Africa;United Kingdom;United States
Benlysta 400 MG powder FOR concentrate FOR solution FOR infusions
   Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
      2009   Phase 3   EUCTR2007-007648-85-NL   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
BI 705564
   Boehringer Ingelheim
      2019   Phase 1   NCT03771885   -
BIIB059
   BIOGEN IDEC RESEARCH LIMITED
      2023   Phase 3   EUCTR2021-006378-22-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005776-35-IT   Argentina;Belgium;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;United Kingdom;United States
   Biogen
      2016   Phase 2   NCT02847598   Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States
      2014   Phase 1   NCT02106897   United States
   Biogen Idec Research Limited
      2023   Phase 3   EUCTR2021-006378-22-RO   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2021-006378-22-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2021-006378-22-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2021-006378-22-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-006378-22-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-006378-22-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-006378-22-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-006378-22-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005776-35-RO   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005776-35-DE   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005776-35-BE   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005775-12-FR   Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005776-35-NL   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005776-35-HU   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005776-35-CZ   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005775-12-GR   Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005775-12-ES   Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States
      2017   Phase 2   EUCTR2015-004359-32-PL   Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States
      2017   Phase 2   EUCTR2015-004359-32-BG   Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States
Biospecimen collection
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
Blinatumomab
   Amgen
      2025   Phase 2   NCT06570798   Belgium;France;Germany;Italy;United States
Blinatumomab 9UG
   Mao Jianhua
      2024   Phase 1   NCT06789107   China
Blisibimod
   Anthera Pharmaceuticals
      2016   Phase 3   NCT02514967   Georgia
      2015   Phase 3   NCT02074020   -
      2013   Phase 3   NCT01395745   Belarus;Brazil;Colombia;Georgia;Guatemala;Hong Kong;India;Korea, Republic of;Malaysia;Mexico;Philippines;Russian Federation;Singapore;Sri Lanka;Taiwan;Thailand
Blood drawing only group C
   Oklahoma Medical Research Foundation
      2009   Phase 1/Phase 2   NCT00987831   United States
Blood sample
   Hospices Civils de Lyon
      2024   Phase 2   NCT06356740   France
   University Hospital, Bordeaux
      2023   -   NCT05698173   France
      2021   -   NCT04276701   France;Germany;Spain
      2020   -   NCT04440566   France
      2018   -   NCT03575156   France
   University Hospital, Brest
      2023   -   NCT05747651   France
      2022   Phase 3   NCT05458622   France
   University Hospital, Tours
      2023   -   NCT05859191   France
Blood sampling
   Hospices Civils de Lyon
      2013   -   NCT01992666   France
BMS-188667
   Bristol Myers Squibb International Corporation
      2006   -   EUCTR2004-004051-19-IT   Germany;Italy;Sweden;United Kingdom
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2008   Phase 2;Phase 3   EUCTR2005-004575-37-GB   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-FR   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-BE   Belgium;France;United Kingdom
      2005   -   EUCTR2004-004051-19-SE   Germany;Italy;Sweden;United Kingdom
      2005   -   EUCTR2004-004051-19-GB   Germany;Italy;Sweden;United Kingdom
      2005   -   EUCTR2004-004051-19-DE   Germany;Italy;Sweden;United Kingdom
      2005   -   EUCTR2004-004051-19-BE   Austria;Belgium;Germany;Italy;Sweden;United Kingdom
      2005   -   EUCTR2004-004051-19-AT   Austria;Germany;Italy;Sweden;United Kingdom
BMS-931699
   Bristol-Myers Squibb
      2014   Phase 2   NCT02265744   Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Puerto Rico;Qatar;Romania;Russian Federation;South Africa;Spain;Taiwan;United States
   Bristol-Myers Squibb International Corporation
      2015   Phase 2   EUCTR2014-002184-14-NL   Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-002184-14-IT   Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-002184-14-HU   Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-002184-14-DE   Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States
      2014   Phase 2   EUCTR2014-002184-14-ES   Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States
BMS-986165
   Bristol-Myers Squibb
      2025   Phase 4   NCT06875960   United States
      2019   Phase 2   NCT03920267   Argentina;Australia;Brazil;Canada;Colombia;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States
      2018   Phase 1   NCT03541564   United States
      2017   Phase 1   NCT03262727   United States
      2017   Phase 2   NCT03252587   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United States
   Bristol-Myers Squibb International Corporation
      2020   Phase 2   EUCTR2018-003471-35-ES   Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Hungary;Israel;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States
      2019   Phase 2   EUCTR2018-003471-35-RO   Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Israel;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States
      2019   Phase 2   EUCTR2018-003471-35-PL   Argentina;Brazil;Canada;Colombia;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States
      2019   Phase 2   EUCTR2018-003471-35-HU   Argentina;Brazil;Canada;Colombia;Hungary;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States
      2019   Phase 2   EUCTR2017-001203-79-ES   Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States
      2018   Phase 2   EUCTR2017-001203-79-PL   Argentina;Australia;Brazil;Colombia;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States
      2018   Phase 2   EUCTR2017-001203-79-DE   Argentina;Australia;Brazil;Canada;Colombia;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States
   Bristol-Myers Squibb international Corporation
      2017   Phase 2   EUCTR2017-001203-79-HU   Argentina;Brazil;Bulgaria;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United States
BMS-986165 capsule
   Bristol-Myers Squibb
      2017   Phase 1   NCT03254784   Netherlands;United States
BMS-986165 tablet
   Bristol-Myers Squibb
      2017   Phase 1   NCT03254784   Netherlands;United States
BMS-986195
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
BMS-986256-06, TLR7/8 antagonist
   Bristol-Myers Squibb International Corporation
      2022   Phase 2   EUCTR2019-004021-25-RO   Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2019-004021-25-PL   Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2019-004021-25-IE   Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2019-004021-25-FR   Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2019-004021-25-ES   Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States
BMS-986326
   Bristol-Myers Squibb
      2023   Phase 1   NCT06013995   Argentina;Bulgaria;Germany;Mexico;Poland;Romania;Spain;United States
BMS986195
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
BNT162b2, bivalent
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
Bone densitometry
   Centre Hospitalier Universitaire, Amiens
      2011   -   NCT02799173   France
Bortezomib
   Charite University, Berlin, Germany
      2014   Phase 2   NCT02102594   Germany
   Tohoku university hospital
      2014   Phase 2   JPRN-UMIN000013508   Japan
      2013   Phase 2   JPRN-UMIN000012227   Japan
BOS161721
   Boston Pharmaceuticals
      2018   Phase 1/Phase 2   NCT03371251   Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States
   Boston Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2018-000305-23-RO   Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States
      2019   Phase 2   EUCTR2018-000305-23-HU   Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States
      2019   Phase 2   EUCTR2018-000305-23-BG   Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States
BR-DIM
   North Shore Long Island Jewish Health System
      2016   Phase 1   NCT02483624   -
Branebrutinib
   Bristol-Myers Squibb
      2020   Phase 2   NCT04186871   Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
Brentuximab vedotin
   Seagen Inc.
      2015   Phase 2   NCT02533570   United States
Brepocitinib
   PFIZER INC
      2021   Phase 2   EUCTR2018-004175-12-IT   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
   Pfizer Inc.
      2019   Phase 2   EUCTR2018-004175-12-PT   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-PL   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-DE   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-BG   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-BE   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
BRL-301
   Bioray Laboratories
      2023   -   NCT05988216   China
      2023   -   NCT05859997   China
BT063
   Biotest
      2015   Phase 2   NCT02554019   Belarus;Georgia;Poland;Serbia
   Biotest AG
      2015   Phase 2   EUCTR2014-005526-35-PL   Belarus;Georgia;Poland;Serbia
Budoprutug
   Tenet Medicines
      2025   Phase 1/Phase 2   NCT06570434   -
Busulfan
   New York Medical College
      2007   Phase 1   NCT00684255   United States
CABA-201
   Cabaletta Bio
      2024   Phase 1/Phase 2   NCT06121297   Spain;United States
Calciferol
   Rajavithi Hospital
      2021   -   NCT05260255   Thailand
Calcitriol
   Chinese University of Hong Kong
      2008   Phase 4   NCT00508898   Hong Kong
   Guilan University of Medical Sciences
      2013   Phase 2   NCT01863641   Iran, Islamic Republic of
Calcium
   Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
      2014   Phase 2   JPRN-UMIN000008230   Japan
   Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College.
      2024   -   ChiCTR2400084812   China
   Nakashima Yasuharu
      2014   Phase 2   JPRN-jRCTs071180052   -
   The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
      2017   -   ChiCTR-INR-17011495   China
Calcium and VIT D
   Cairo University
      2022   -   NCT05392790   Egypt
Campath
   New York Medical College
      2007   Phase 1   NCT00684255   United States
CAR-T cell
   Wuhan Union Hospital, China
      2025   -   NCT06900764   China
CAR-T therapy
   Beijing GoBroad Hospital
      2025   Phase 1   NCT06822881   China
CART19
   Children's Hospital of Philadelphia
      2025   Phase 1/Phase 2   NCT06839976   United States
CB-010
   Caribou Biosciences, Inc.
      2025   Phase 1   NCT06752876   United States
CBC
   Sohag University
      2024   -   NCT06294483   Egypt
CC-220
   Celgene
      2017   Phase 2   NCT03161483   Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States
      2014   Phase 2   NCT02185040   United States
   Celgene Corporation
      2017   Phase 2   EUCTR2016-004574-17-HU   Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States
      2017   Phase 2   EUCTR2016-004574-17-FR   Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States
      2017   Phase 2   EUCTR2016-004574-17-ES   Argentina;Belgium;Brazil;Canada;Colombia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States
      2017   Phase 2   EUCTR2016-004574-17-DE   Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States
      2017   Phase 2   EUCTR2016-004574-17-BE   Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States
CC-97540
   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
      2023   Phase 1   NCT05869955   Belgium;France;Germany;Italy;Spain;United States
CC312
   CytoCares Inc
      2024   Early Phase 1   NCT06888960   China
CCX168
   Amgen
      2009   Phase 1   NCT05984251   Switzerland
CD19 CAR-T cell infusion
   Wuhan Union Hospital, China
      2024   Phase 1/Phase 2   NCT06106906   China
CD19 CAR-T cells
   Beijing GoBroad Hospital
      2024   Phase 1/Phase 2   NCT06585514   China
   National University of Malaysia
      2025   Phase 1   NCT06710717   Malaysia
CD19 universal CAR-?D T cells
   Wuhan Union Hospital, China
      2024   Phase 1/Phase 2   NCT06106893   China
CD19 universal CAR-T cells
   The Children's Hospital of Zhejiang University School of Medicine
      2024   Phase 1   NCT06691152   China
CD19- bcma CAR-T cells
   Essen Biotech
      2024   Phase 1/Phase 2   NCT06350110   China
CD19-bcma CAR-T cells infusion
   Beijing GoBroad Hospital
      2025   Phase 1/Phase 2   NCT06947460   China
CD19-CAR-DNT cells
   Guangdong Ruishun Biotech Co., Ltd
      2024   Phase 1   NCT06340490   China
   RenJi Hospital
      2023   Phase 1   NCT06316076   China
CD19/bcma CAR-T cell therapy
   Wuhan Union Hospital, China
      2025   Phase 1   NCT06349343   China
CD20/BCMA-directed CAR-T cells
   RenJi Hospital
      2024   Phase 1   NCT06249438   China
CD34+ peripheral blood stem cell reinfusion
   Northwestern Memorial Hospital
      2001   Phase 1   NCT00017641   United States
CDP3194
   UCB Inc
      2008   -   EUCTR2007-002589-37-LT   Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom
      2008   -   EUCTR2007-002589-37-HU   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-002589-37-GB   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   -   EUCTR2007-002589-37-ES   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-002589-37-BE   Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom
      2008   -   EUCTR2007-002566-35-LT   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   -   EUCTR2007-002566-35-HU   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   -   EUCTR2007-002566-35-GB   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-002566-35-ES   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   -   EUCTR2007-002566-35-BE   Belgium;Hungary;Lithuania;Spain;United Kingdom
   UCB Inc.
      2012   Phase 3   EUCTR2010-020859-30-IT   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-020859-30-EE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-018563-41-LT   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
      2012   -   EUCTR2010-018563-41-EE   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
      2011   -   EUCTR2010-020859-30-LT   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2010-020859-30-HU   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2010-020859-30-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2011   -   EUCTR2010-020859-30-ES   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Spain;United Kingdom
      2011   Phase 3   EUCTR2010-020859-30-DE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2011   -   EUCTR2010-020859-30-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2010-020859-30-BG   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2010-020859-30-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2011   -   EUCTR2010-018565-26-IT   Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom
      2011   -   EUCTR2010-018565-26-HU   Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom
      2011   Phase 3   EUCTR2010-018565-26-GB   Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom
      2011   -   EUCTR2010-018565-26-ES   Germany;Hungary;Italy;Spain;United Kingdom
      2011   -   EUCTR2010-018565-26-DE   Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom
      2011   -   EUCTR2010-018563-41-IT   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
      2011   Phase 3   EUCTR2010-018563-41-GB   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
      2011   -   EUCTR2010-018563-41-ES   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;United Kingdom
      2011   -   EUCTR2010-018563-41-DE   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
      2011   -   EUCTR2010-018563-41-CZ   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
      2011   -   EUCTR2010-018563-41-BG   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
      2011   -   EUCTR2010-018563-41-BE   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
CDP7657
   UCB Biopharma SPRL
      2016   Phase 2   EUCTR2015-004457-40-PL   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2015-004457-40-HU   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2015-004457-40-ES   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2015-004457-40-DE   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2015-004457-40-BG   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
   UCB Biopharma SRL
      2023   Phase 3   EUCTR2019-003409-83-IT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2019-003409-83-DK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2019-003409-83-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2019-003407-35-BE   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-RO   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-PT   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-PL   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-IT   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-FR   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-ES   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-DK   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-DE   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003406-27-DK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003409-83-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003409-83-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003409-83-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003406-27-RO   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003406-27-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003406-27-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-IT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-003409-83-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-003409-83-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-003407-35-AT   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-003406-27-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
   UCB Pharma
      2013   Phase 1   NCT01764594   Belgium;Bulgaria;Germany;Poland;Romania;Russian Federation;Spain
      2010   Phase 1   NCT01093911   Belgium;Bulgaria;Germany
Cellcept
   Bristol-Myers Squibb International Corporation
      2008   Phase 2;Phase 3   EUCTR2005-004575-37-GB   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-FR   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-BE   Belgium;France;United Kingdom
   Cambridge University Hospitals NHS Foundation Trust
      2005   Phase 2   EUCTR2005-002207-16-GB   United Kingdom
   Guy's & St Thomas' NHS Foundation Trust
      2005   Phase 4   EUCTR2005-001688-74-GB   United Kingdom
Cenerimod
   IDORSIA PHARMACEUTICALS LTD
      2019   Phase 2   EUCTR2018-001808-11-IT   Bulgaria;Chile;China;Colombia;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
   Idorsia Pharmaceuticals Ltd
      2023   Phase 3   EUCTR2022-002815-47-PT   Chile;China;Czech Republic;Czechia;Georgia;Germany;Japan;Mexico;Peru;Philippines;Poland;Portugal;Serbia;South Africa;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002815-47-DE   Chile;China;Czech Republic;Czechia;Georgia;Germany;Japan;Mexico;Peru;Philippines;Poland;Portugal;Serbia;South Africa;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002815-47-CZ   Chile;China;Czech Republic;Czechia;Georgia;Germany;Japan;Mexico;Peru;Philippines;Poland;Portugal;Serbia;South Africa;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002814-17-RO   Argentina;Brazil;Bulgaria;China;Colombia;France;Greece;Korea, Republic of;Malaysia;Mexico;Philippines;Poland;Romania;Taiwan;Thailand;United States
      2023   Phase 3   EUCTR2022-002814-17-GR   Argentina;Brazil;Bulgaria;China;Colombia;France;Greece;Korea, Republic of;Malaysia;Mexico;Philippines;Poland;Romania;Taiwan;Thailand;United States
      2023   Phase 3   EUCTR2022-002814-17-FR   Argentina;Brazil;Bulgaria;China;Colombia;France;Greece;Korea, Republic of;Malaysia;Mexico;Philippines;Poland;Romania;Taiwan;Thailand;United States
      2023   Phase 3   EUCTR2022-002814-17-BG   Argentina;Brazil;Bulgaria;China;Colombia;France;Greece;Korea, Republic of;Malaysia;Mexico;Philippines;Poland;Romania;Taiwan;Thailand;United States
      2020   Phase 2   EUCTR2018-001808-11-GR   Bulgaria;Chile;China;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001808-11-PL   Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001808-11-HU   Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001808-11-FR   Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001808-11-ES   Bulgaria;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001808-11-DE   Bulgaria;China;Czech Republic;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001808-11-BG   Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 2   EUCTR2018-001808-11-GB   Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
   Idorsia Pharmaceuticals Ltd.
      2024   Phase 3   NCT06475742   Argentina;Bulgaria;Chile;Czechia;Georgia;Germany;Peru;Philippines;Poland;Puerto Rico;Romania;South Africa;Spain;United States
      2023   Phase 3   NCT05672576   Chile;Czechia;Georgia;Germany;Japan;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Puerto Rico;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   NCT05648500   Argentina;Brazil;Bulgaria;Colombia;France;Greece;Korea, Republic of;Mexico;Philippines;Poland;Romania;Taiwan;Thailand;Ukraine;United States
      2015   Phase 1/Phase 2   NCT02472795   Belarus;Bulgaria;Georgia;Russian Federation;Ukraine;United States
   Yokoyama Yoshinari
      2023   Phase 3   JPRN-jRCT2051230027   Africa region;Asia-Pacific region;European region;Japan;North Central South America;United States
      2021   Phase 2   JPRN-jRCT2011210019   -
Cenerimod 0.5 MG
   Idorsia Pharmaceuticals Ltd.
      2018   Phase 2   NCT03742037   Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;Mexico;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
Cenerimod 1 MG
   Idorsia Pharmaceuticals Ltd.
      2018   Phase 2   NCT03742037   Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;Mexico;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
Cenerimod 2 MG
   Idorsia Pharmaceuticals Ltd.
      2018   Phase 2   NCT03742037   Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;Mexico;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
Cenerimod 4 MG
   Idorsia Pharmaceuticals Ltd.
      2018   Phase 2   NCT03742037   Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;Mexico;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
CEP-33457
   Cephalon, Inc.
      2011   -   EUCTR2010-019293-32-DE   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2011   Phase 3   EUCTR2010-019293-32-BE   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   Phase 3   NCT01240694   Belgium;Czech Republic;Czechia;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United Kingdom;United States
      2010   -   EUCTR2010-019293-32-PT   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-019293-32-HU   Czech Republic;Hungary;Portugal;Spain
      2010   Phase 3   EUCTR2010-019293-32-ES   Belgium;Czech Republic;Germany;Hungary;Portugal;Spain
      2010   -   EUCTR2010-019293-32-CZ   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-018383-16-PT   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-018383-16-HU   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   Phase 2   EUCTR2010-018383-16-FR   Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain
      2010   Phase 2   EUCTR2010-018383-16-ES   Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain
      2010   -   EUCTR2010-018383-16-DE   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-018383-16-CZ   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   Phase 2   EUCTR2010-018383-16-BE   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
Certolizumab pegol
   University of Utah
      2021   Phase 2   EUCTR2020-001177-78-FR   France;United States
Cervarix suspensie voor injectie
   University Medical Center Utrecht
      2009   -   EUCTR2008-008169-36-NL   Netherlands
CFZ533
   Novartis Farmacéutica, S.A.
      2018   Phase 2   EUCTR2018-001508-12-ES   Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand
   Novartis Pharma AG
      2019   Phase 2   EUCTR2018-001508-12-FR   Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand
      2018   Phase 2   EUCTR2018-001508-12-DE   Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States
      2018   Phase 2   EUCTR2018-001508-12-CZ   Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States
   Novartis Pharmaceuticals
      2018   Phase 2   NCT03656562   Argentina;Australia;China;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States
Cholecalciferol
   Assistance Publique - Hôpitaux de Paris
      2010   -   NCT01413230   France
   Medical University of South Carolina
      2011   Phase 2   NCT01911169   United States
      2006   Phase 1   NCT00418587   United States
   ROSA MARIA RODRIGUES PEREIRA
      2012   -   NCT01892748   Brazil
Cholecalciferol and C. xanthorrhiza
   Saiful Anwar Hospital
      2016   -   NCT03155477   -
Ciclofosfamide
   A.S.L. TO 2
      2022   Phase 3   EUCTR2021-006544-26-IT   Italy
Ciclosporin
   Manuel Praga Terente
      2010   -   EUCTR2009-017273-38-ES   Spain
Ciclosporina
   Manuel Praga Terente
      2010   -   EUCTR2009-017273-38-ES   Spain
Cimzia
   University of Utah
      2021   Phase 2   EUCTR2020-001177-78-FR   France;United States
Clinical laboratory evaluations - biochemistry
   LiveKidney.Bio
      2025   Phase 1   NCT06737380   United States
Clinical laboratory evaluations - hematology
   LiveKidney.Bio
      2025   Phase 1   NCT06737380   United States
Clinical laboratory evaluations - serology
   LiveKidney.Bio
      2025   Phase 1   NCT06737380   United States
CLN-978
   Cullinan Therapeutics Inc.
      2025   Phase 1   NCT06613360   Australia;Georgia;Moldova, Republic of;United States
Clopidogrel
   Nakashima Yasuharu
      2014   Phase 2   JPRN-jRCTs071180052   -
CM313 injection
   Keymed Biosciences Co.Ltd
      2025   Phase 2   NCT06791772   China
CNCT19 cell injection
   Peking Union Medical College Hospital
      2023   Early Phase 1   NCT05930314   China
CNTO1275
   Janssen-Cilag International N.V.
      2015   Phase 2   EUCTR2014-005000-19-PL   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-005000-19-HU   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-005000-19-ES   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-005000-19-DE   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
   Janssen-Cilag International NV
      2019   Phase 3   EUCTR2017-001489-53-PT   Argentina;Bulgaria;Canada;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-PL   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-LT   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-HU   Argentina;Australia;Bulgaria;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-ES   Argentina;Australia;Bulgaria;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-DE   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-BG   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
CNTY-101
   Century Therapeutics, Inc.
      2025   Phase 1   NCT06255028   United States
Coaching sessions
   Northwestern University
      2014   -   NCT02281513   United States
Collection OF samples
   Institut National de la Santé Et de la Recherche Médicale, France
      2021   -   NCT04902807   -
Computed tomography
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States
Concomitant medication
   Janssen Research & Development, LLC
      2015   Phase 2   NCT02349061   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United Kingdom;United States
Conjugated equine estrogens 0.625 MG/D + MPA 5 MG/D/10D
   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
      1997   Phase 4   NCT00392093   Mexico
Continuation OF azathioprine
   Erasmus Medical Center
      2007   Phase 3   NCT00504244   Netherlands
Conventional pharmacotherapy
   Yijun Luo
      2025   -   NCT06898489   China
Conventional therapy
   Guanmin Gao
      2023   Phase 2   NCT05929248   -
   Xuzhou NO.1 People's Hospital
      2022   Phase 4   ChiCTR2200064438   China
Corn starch
   Michelle Petri M.D.,MPH
      2009   Phase 4   NCT00828178   United States
Corticosteroids
   Bristol-Myers Squibb
      2007   Phase 2/Phase 3   NCT00430677   Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States
   Genentech, Inc.
      2008   Phase 3   NCT00626197   United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00230035   United States
Covid-19 vaccine
   Paul R Fortin
      2022   Phase 2/Phase 3   NCT05236491   Canada
Creatine
   University of Sao Paulo
      2011   -   NCT01217320   Brazil
Crestor
   Imperial College
      2010   Phase 4   EUCTR2006-006214-16-GB   United Kingdom
CSA
   Manuel Praga Terente
      2010   -   EUCTR2009-017273-38-ES   Spain
CTLA4IG
   Bristol-Myers Squibb International Corporation
      2008   Phase 2;Phase 3   EUCTR2005-004575-37-GB   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-FR   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-BE   Belgium;France;United Kingdom
      2005   -   EUCTR2004-004051-19-SE   Germany;Italy;Sweden;United Kingdom
      2005   -   EUCTR2004-004051-19-GB   Germany;Italy;Sweden;United Kingdom
      2005   -   EUCTR2004-004051-19-DE   Germany;Italy;Sweden;United Kingdom
      2005   -   EUCTR2004-004051-19-BE   Austria;Belgium;Germany;Italy;Sweden;United Kingdom
      2005   -   EUCTR2004-004051-19-AT   Austria;Germany;Italy;Sweden;United Kingdom
CUG252
   Cugene Inc.
      2023   Phase 1   NCT05866861   United States
      2021   Phase 1   NCT05328557   United States
Cumulative corticosteroid exposure
   GlaxoSmithKline
      2012   -   NCT01616472   -
Cyclophosphamide
   Adicet Therapeutics
      2024   Phase 1   NCT06375993   United States
   Artiva Biotherapeutics, Inc.
      2024   Phase 1   NCT06265220   United States
   AstraZeneca
      2025   Phase 1/Phase 2   NCT06897930   United States
   Chinese SLE Treatment And Research Group
      2015   Phase 3   NCT02444728   China
   EdiGene Inc.
      2024   Phase 1   NCT06373991   China
   Fairview University Medical Center
      2000   -   NCT00006055   United States
   Fate Therapeutics
      2024   Phase 1   NCT06308978   United States
   Fen Li
      2022   Phase 4   NCT05666336   China
   Genentech, Inc.
      2025   Phase 1   NCT06984341   -
      2008   Phase 3   NCT00626197   United States
   IRIS Research and Development, LLC
      2024   Phase 1   NCT06581562   United States
   ISTITUTO GIANNINA GASLINI
      2006   Phase 3   EUCTR2005-003957-28-IT   Belgium;Denmark;Italy
   Institute of Rheumatology, Prague
      2002   Phase 2   NCT00976300   Czech Republic
   Istituto Giannina Gaslini
      2006   -   EUCTR2005-003957-28-DK   Denmark;Italy
   Johns Hopkins University
      1997   -   NCT00010400   United States
   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
      2023   Phase 1   NCT05869955   Belgium;France;Germany;Italy;Spain;United States
   Miltenyi Biomedicine GmbH
      2025   Phase 1   NCT06708845   -
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00076752   United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2004   Phase 1/Phase 2   NCT00094380   United States
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1986   Phase 2   NCT00001212   United States
   Northwestern Memorial Hospital
      2001   Phase 1   NCT00017641   United States
   Shanghai GeneChem Co., Ltd.
      2017   Phase 1   NCT03030976   China
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 1/Phase 2   NCT02080195   United States
   Sun Yat-sen University
      2010   -   NCT01060410   China
   The Second Hospital of Shanxi Medical University
      2021   -   ChiCTR2200055471   China
   University Hospital Gent
      -   Phase 3   EUCTR2005-003957-28-BE   Belgium;Denmark;Italy
   University of Sao Paulo General Hospital
      2018   -   NCT03492255   Brazil
   Zhejiang Chinese Medical University
      2021   -   ChiCTR2100048796   China
      2015   -   ChiCTR-ONC-15007547   China
Cyclophosphamide LD
   Columbia University
      2024   Phase 1   NCT06518668   United States
Cyclophosphamide-prednisone-azathioprine
   Istituto Giannina Gaslini
      2006   Phase 3   NCT00336414   Italy
Cyclosporin A
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1986   Phase 2   NCT00001212   United States
Cyclosporine
   Fairview University Medical Center
      2000   -   NCT00006055   United States
   The Third Affiliated Hospital, Southern Medical University
      2018   -   ChiCTR1800019308   China
Cyclosporine A
   Institute of Rheumatology, Prague
      2002   Phase 2   NCT00976300   Czech Republic
Cymbalta
   Dr. Jesus Gutierrez Stone
      2010   -   NCT01269866   United States
Cytarabine
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004643   -
Cytokines and chemokine profiling
   LiveKidney.Bio
      2025   Phase 1   NCT06737380   United States
Dapagliflozin
   Dept. Rheumatology, Renji Hospital South Campus
      2018   Phase 4 study   ChiCTR1800015030   China
Dapirolizumab pegol
   Matano Mizuho
      2023   Phase 3   JPRN-jRCT2071220073   Argentina;Austria;Belgium;Canada;Chile;China;Denmark;France;Germany;Greece;Italy;Japan;Peru;Poland;Portugal;Serbia;South Korea;Spain;Taiwan;United Kingdom;United States
   UCB Biopharma S.P.R.L.
      2016   Phase 2   NCT02804763   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
   UCB Biopharma SPRL
      2016   Phase 2   EUCTR2015-004457-40-PL   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2015-004457-40-HU   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2015-004457-40-ES   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2015-004457-40-DE   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2015-004457-40-BG   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
   UCB Biopharma SRL
      2023   Phase 3   EUCTR2019-003409-83-IT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2019-003409-83-DK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2019-003409-83-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2019-003407-35-BE   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-RO   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-PT   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-PL   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-IT   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-FR   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-ES   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-DK   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-DE   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003406-27-DK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   NCT04976322   Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Romania;Serbia;Spain;Taiwan;United States
      2021   Phase 3   EUCTR2019-003409-83-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003409-83-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003409-83-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003406-27-RO   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003406-27-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003406-27-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-IT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-003409-83-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-003409-83-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-003407-35-AT   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-003406-27-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Daratumumab
   Charité - Universitätsmedizin Berlin
      2021   Phase 2   EUCTR2021-000962-14-DE   Germany
Daratumumab injection
   Charite University, Berlin, Germany
      2021   Phase 2   NCT04810754   -
Darzalex
   Charité - Universitätsmedizin Berlin
      2021   Phase 2   EUCTR2021-000962-14-DE   Germany
Daxdilimab
   Amgen
      2022   Phase 2   NCT05430854   Argentina;Greece;India;Mexico;Poland;Serbia;Spain;Taiwan;United States
   Horizon Therapeutics Ireland DAC
      2022   Phase 2   EUCTR2022-000855-35-PL   Argentina;Greece;India;Mexico;Poland;Serbia;Spain;Taiwan;United States
      2022   Phase 2   EUCTR2022-000855-35-GR   Argentina;Greece;India;Mexico;Poland;Serbia;Spain;Taiwan;United States
      2022   Phase 2   EUCTR2022-000855-35-ES   Argentina;Greece;India;Mexico;Poland;Serbia;Spain;Taiwan;United States
DB-2304
   DualityBio Inc.
      2024   Phase 1   NCT06625671   Australia
Dehydroepiandrosterone
   National Center for Research Resources (NCRR)
      1996   Phase 3   NCT00004662   -
      1995   Phase 2   NCT00004665   -
      1994   Phase 2/Phase 3   NCT00004795   -
   UMC Utrecht
      2000   Phase 2   NCT00391924   Netherlands
   University of Michigan
      2003   Phase 2/Phase 3   NCT00189124   United States
Deltacortene*20CPR 5MG
   NOVARTIS FARMA
      2006   -   EUCTR2006-002107-13-IT   France;Germany;Greece;Hungary;Italy;Spain;United Kingdom
Depletion OF CD3/CD19 IN AN autologous stem cell transplant
   Stephan Grupp MD PhD
      2025   Phase 2   NCT05029336   United States
Descartes-08
   Cartesian Therapeutics
      2024   Phase 2   NCT06038474   United States
Deucravacitinib
   Bristol-Myers Squibb
      2023   Phase 3   NCT05620407   Argentina;Australia;Brazil;Bulgaria;Chile;Czechia;Greece;Hungary;India;Japan;Mexico;Peru;Poland;Portugal;Puerto Rico;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2023   Phase 3   NCT05617677   Argentina;Brazil;Bulgaria;Canada;China;Colombia;France;Germany;Hong Kong;India;Ireland;Italy;Korea, Republic of;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Puerto Rico;Romania;Slovakia;South Africa;Turkey;United States
   Hobar Coburn
      2023   Phase 3   JPRN-jRCT2011230001   Argentina;Australia;Brazil;Chile;Czech Republic;Greece;Hungary;Japan;Mexico;Peru;Poland;Portugal;Singapore;Spain;Taiwan;USA;United Kingdom
Dhea
   University of Michigan
      2003   Phase 2/Phase 3   NCT00189124   United States
Dihydroartemisinin tablet
   Kunming Pharmaceuticals, Inc.
      2018   Phase 2   NCT03396393   -
Dimethylfumarat
   Universitätsklinikum Münster
      2011   -   EUCTR2010-023645-29-DE   Germany
Diphenhydramine
   Genentech, Inc.
      2006   Phase 3   NCT00381810   United States
      2005   Phase 2/Phase 3   NCT00137969   Canada;United States
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00076752   United States
Diphenhydramine hydrochloride
   Hoffmann-La Roche
      2021   Phase 3   NCT04963296   Argentina;Brazil;Czechia;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
Docosahexaenoic acid
   GreenPark Healthcare Trust
      2004   Phase 4   EUCTR2004-004404-21-GB   United Kingdom
Doppler ultrasound
   Centre Hospitalier Universitaire, Amiens
      2011   -   NCT02799173   France
Drug free
   Peking Union Medical College Hospital
      2016   -   NCT02842814   China
Drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom
   Groupe Hospitalier Pitie-Salpetriere
      2018   -   NCT03480529   France
DS-7011A
   Daiichi Sankyo
      2023   Phase 1/Phase 2   NCT05638802   United States
   Daiichi Sankyo, Inc.
      2022   Phase 1   NCT05203692   United States
DZP
   UCB Biopharma S.P.R.L.
      2016   Phase 2   NCT02804763   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
   UCB Biopharma SPRL
      2016   Phase 2   EUCTR2015-004457-40-PL   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2015-004457-40-HU   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2015-004457-40-ES   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2015-004457-40-DE   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2015-004457-40-BG   Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States
   UCB Biopharma SRL
      2024   Phase 3   NCT06617325   Argentina;Belgium;China;Denmark;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Poland;Puerto Rico;Serbia;Spain;Taiwan;United States
      2023   Phase 3   EUCTR2019-003409-83-IT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2019-003409-83-DK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2019-003409-83-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2019-003407-35-BE   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-RO   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003409-83-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-PT   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-PL   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-FR   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-ES   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-DK   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003407-35-DE   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003406-27-DK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003409-83-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003409-83-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003409-83-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003406-27-RO   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003406-27-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2019-003406-27-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   NCT04294667   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-IT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003406-27-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-003409-83-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-003409-83-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-003407-35-AT   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2019-003406-27-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
E6742
   Eisai Co., Ltd.
      2022   Phase 1/Phase 2   NCT05278663   Japan
Edratide
   TEVA Pharmaceutical Industries, Ltd.
      2005   -   EUCTR2005-001391-12-HU   Germany;Hungary;Italy;Spain;United Kingdom
      2005   Phase 2   EUCTR2005-001391-12-GB   Germany;Hungary;Italy;Spain;United Kingdom
      2005   Phase 2   EUCTR2005-001391-12-ES   Germany;Hungary;Italy;Spain;United Kingdom
      2005   -   EUCTR2005-001391-12-DE   Germany;Hungary;Italy;Spain;United Kingdom
   Teva Pharmaceutical Industries
      2005   Phase 2   NCT00203151   United States
Edratide acetate
   TEVA
      2005   -   EUCTR2005-001391-12-IT   Germany;Hungary;Italy;Spain;United Kingdom
Efavaleukin alfa
   AMGEN INC.
      2021   Phase 2   EUCTR2020-003509-72-IT   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
   Amgen
      2021   Phase 2   NCT04680637   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
      2018   Phase 1   NCT03451422   France;Germany;Poland;United States
   Amgen Inc.
      2021   Phase 2   EUCTR2020-003509-72-PL   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-GR   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-FR   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-ES   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-BG   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-AT   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United States
   Kimura Takeshi
      2021   Phase 2   JPRN-jRCT2041210076   Austria;Bulgaria;Chile;Colombia;France;Greece,;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
Eicosapentaenoic acid
   GreenPark Healthcare Trust
      2004   Phase 4   EUCTR2004-004404-21-GB   United Kingdom
Electrocardiogram
   LiveKidney.Bio
      2025   Phase 1   NCT06737380   United States
Elsubrutinib
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 2   EUCTR2020-001690-72-IT   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000638-20-IT   Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
   AbbVie
      2020   Phase 2   NCT04451772   Argentina;Australia;Bulgaria;Canada;China;Colombia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   NCT03978520   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States
   AbbVie Deutschland GmbH & Co. KG
      2021   Phase 2   EUCTR2020-001690-72-DE   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001690-72-BG   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001690-72-NL   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001690-72-HU   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000638-20-DE   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000638-20-BG   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000638-20-HU   Argentina;Australia;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
   Yamazaki Hayato
      2021   Phase 2   JPRN-jRCT2031210119   Argentina;Bulgaria;China;Germany;Hungary;Japan;Mexico;Netherlands;Poland;Puerto Rico;Spain;Taiwan;United States
Emapalumab
   Ochiai Kazuya
      2023   Phase 2-3   JPRN-jRCT2031220187   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Swedish Orphan Biovitrum
      2021   Phase 3   NCT05001737   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Swedish Orphan Biovitrum AG (Sobi AG)
      2022   Phase 2;Phase 3   EUCTR2021-001577-24-CZ   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-001577-24-SE   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
Endoxan
   A.S.L. TO 2
      2022   Phase 3   EUCTR2021-006544-26-IT   Italy
Engineering OF chimeric antigen receptors targeting CD19 IN allogeneic T cells
   Beijing Immunochina Medical Science & Technology Co., Ltd.
      2025   Early Phase 1   NCT06886919   -
Enpatoran
   Ishii Kyoko
      2023   Phase 2   JPRN-jRCT2071220084   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Greece;Israel;Japan;Korea;Mauritius;Mexico;Moldova;Philippines;Poland;Puerto Rico;Romania;Serbia;South Africa;Spain;Sweden;Taiwan;Ukrine;United States
      2022   Phase 2   JPRN-jRCT2031210627   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Greece;Israel;Japan;Mauritius;Mexico;Moldova;Philippines;Poland;Puerto Rico;Russia;Serbia;South Africa;Spain;Sweden;Ukrine;United States
Enpatoran 25MG
   Merck Healthcare KGaA
      2023   Phase 2   EUCTR2022-000239-21-RO   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
      2022   Phase 2   EUCTR2022-000239-21-ES   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United States
      2022   Phase 2   EUCTR2022-000239-21-BG   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
      2022   Phase 2   EUCTR2021-004648-27-RO   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Sweden;Taiwan;United States
      2022   Phase 2   EUCTR2021-004648-27-ES   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Hungary;Japan;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States
      2022   Phase 2   EUCTR2021-004648-27-BG   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
Enpatoran 50MG
   Merck Healthcare KGaA
      2022   Phase 2   EUCTR2022-000239-21-BG   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
      2022   Phase 2   EUCTR2021-004648-27-RO   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Sweden;Taiwan;United States
      2022   Phase 2   EUCTR2021-004648-27-BG   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
Enpatoran high dose
   EMD Serono Research & Development Institute, Inc.
      2022   Phase 2   NCT05162586   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Germany;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
Enpatoran LOW dose
   EMD Serono Research & Development Institute, Inc.
      2022   Phase 2   NCT05162586   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Germany;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
Enpatoran medium dose
   EMD Serono Research & Development Institute, Inc.
      2022   Phase 2   NCT05162586   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Germany;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
Enteric-coated mycophenolate sodium
   Hospital Universitari Vall d'Hebron Research Institute
      2009   Phase 4   NCT01112215   Spain
EPA and DHA supplementation
   University of Sao Paulo
      2014   -   NCT01956188   Brazil
Epatuzumab
   IMMUNOMEDICS
      2005   -   EUCTR2005-000706-31-IT   Germany;Italy;Spain;United Kingdom
Epratuzumab
   Immunomedics, Inc.
      2006   Phase 3   EUCTR2005-000705-59-HU   Germany;Hungary;Italy;Slovakia;Spain;United Kingdom
      2005   -   EUCTR2005-000706-31-GB   Germany;Italy;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-000706-31-ES   Belgium;Germany;Italy;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-000705-59-SK   Germany;Hungary;Italy;Slovakia;Spain;United Kingdom
      2005   -   EUCTR2005-000705-59-GB   Germany;Hungary;Italy;Spain;United Kingdom
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2001   Phase 1   NCT00011908   United States
   UCB Inc
      2008   -   EUCTR2007-002589-37-LT   Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom
      2008   -   EUCTR2007-002589-37-HU   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-002589-37-GB   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   -   EUCTR2007-002589-37-ES   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-002589-37-BE   Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom
      2008   -   EUCTR2007-002566-35-LT   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   -   EUCTR2007-002566-35-HU   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   -   EUCTR2007-002566-35-GB   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-002566-35-ES   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   -   EUCTR2007-002566-35-BE   Belgium;Hungary;Lithuania;Spain;United Kingdom
   UCB Inc.
      2012   Phase 3   EUCTR2010-020859-30-IT   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-020859-30-EE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-018563-41-LT   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
      2012   -   EUCTR2010-018563-41-EE   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
      2011   -   EUCTR2010-020859-30-LT   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2010-020859-30-HU   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2010-020859-30-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2011   -   EUCTR2010-020859-30-ES   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Spain;United Kingdom
      2011   Phase 3   EUCTR2010-020859-30-DE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2011   -   EUCTR2010-020859-30-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2010-020859-30-BG   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2010-020859-30-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2011   -   EUCTR2010-018565-26-IT   Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom
      2011   -   EUCTR2010-018565-26-HU   Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom
      2011   Phase 3   EUCTR2010-018565-26-GB   Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom
      2011   -   EUCTR2010-018565-26-ES   Germany;Hungary;Italy;Spain;United Kingdom
      2011   -   EUCTR2010-018565-26-DE   Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom
      2011   -   EUCTR2010-018563-41-IT   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
      2011   Phase 3   EUCTR2010-018563-41-GB   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
      2011   -   EUCTR2010-018563-41-ES   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;United Kingdom
      2011   -   EUCTR2010-018563-41-DE   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
      2011   -   EUCTR2010-018563-41-CZ   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
      2011   -   EUCTR2010-018563-41-BG   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
      2011   -   EUCTR2010-018563-41-BE   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom
   UCB Pharma
      2012   Phase 2   NCT01534403   Japan
      2011   Phase 3   NCT01408576   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2010   Phase 3   NCT01262365   Australia;Belgium;Brazil;Bulgaria;Czech Republic;Czechia;Estonia;France;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Puerto Rico;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2010   Phase 3   NCT01261793   Brazil;Canada;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2008   Phase 2   NCT00660881   Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom;United States
      2008   Phase 2   NCT00624351   Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom;United States
      2007   Phase 3   NCT00382837   Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovakia;Spain;United Kingdom;United States
      2006   Phase 2   NCT00383513   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2005   Phase 3   NCT00383214   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2005   Phase 2   NCT00113971   United States
      2005   Phase 3   NCT00111306   Belgium;Hungary;Netherlands;Spain;United Kingdom;United States
   UCB Pharma Inc.
      2006   -   EUCTR2005-000706-31-DE   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2005-000706-31-BE   Belgium;Germany;Italy;Spain;United Kingdom
   UCB Pharma, Inc
      2006   -   EUCTR2005-000705-59-DE   Germany;Hungary;Italy;Spain;United Kingdom
Epratuzumab 100 MG
   UCB Pharma
      2011   Phase 1/Phase 2   NCT01449071   Japan
Epratuzumab 1200 MG
   UCB Pharma
      2011   Phase 1/Phase 2   NCT01449071   Japan
Epratuzumab 400 MG
   UCB Pharma
      2011   Phase 1/Phase 2   NCT01449071   Japan
Epratuzumab 600 MG
   UCB Pharma
      2011   Phase 1/Phase 2   NCT01449071   Japan
Epratuzumab IV
   UCB Biopharma S.P.R.L.
      2014   Phase 1   NCT02306629   United Kingdom
Epratuzumab SC
   UCB Biopharma S.P.R.L.
      2014   Phase 1   NCT02306629   United Kingdom
Equecabtagene autoleucel injection
   Tongji Hospital
      2025   -   NCT06902844   China
ERL080A
   Novartis Pharma Services AG
      2006   Phase 2   EUCTR2005-003070-19-HU   Hungary
ESK-001
   Alumis Inc
      2023   Phase 2   NCT05966480   Argentina;Bulgaria;Chile;Colombia;Croatia;Denmark;Georgia;Germany;Hungary;India;Korea, Republic of;Mexico;Peru;Philippines;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
Ethinyl estradiol
   Bristol-Myers Squibb
      2017   Phase 1   NCT03262727   United States
   National Center for Research Resources (NCRR)
      2000   -   NCT00006133   United States
Ethylhydrogenfumarat, calciumsalz
   Universitätsklinikum Münster
      2011   -   EUCTR2010-023645-29-DE   Germany
Ethylhydrogenfumarat, magnesiumsalz
   Universitätsklinikum Münster
      2011   -   EUCTR2010-023645-29-DE   Germany
Ethylhydrogenfumarat, zinksalz
   Universitätsklinikum Münster
      2011   -   EUCTR2010-023645-29-DE   Germany
Evobrutinib
   Merck Biopharma Co., Ltd
      2017   Phase 2   JPRN-jRCT2080223900   Africa;Asia except Japan;Europe;Japan;North America;South America
   Merck KGaA
      2017   Phase 2   EUCTR2016-002950-19-PL   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States
      2017   Phase 2   EUCTR2016-002950-19-DE   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States
      2017   Phase 2   EUCTR2016-002950-19-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States
Extended release dipyridamole 200MG/aspirin 25MG
   Oklahoma Medical Research Foundation
      2013   -   NCT01781611   United States
Ezetimibe+simvastatin drug combination
   Peking Union Medical College Hospital
      2015   Phase 0   NCT02548936   China
FAN beam CT scan
   Centre Hospitalier Universitaire, Amiens
      2011   -   NCT02799173   France
Fecal microbiota
   Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College
      2021   Phase 2   ChiCTR2100052493   China
   The Second Xiangya Hospital of Central South University
      2020   Phase 0   ChiCTR2000036352   China
Fibrinogen TO albumin ratio and C-reactive TO albumin ratio
   Sohag University
      2024   -   NCT06404723   -
Filgrastim
   Fairview University Medical Center
      2000   -   NCT00006055   United States
   Johns Hopkins University
      1997   -   NCT00010400   United States
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00076752   United States
   Northwestern Memorial Hospital
      2001   Phase 1   NCT00017641   United States
Fish OIL
   University of Texas Southwestern Medical Center
      2012   Phase 2   NCT02021513   United States
Fitbit activity monitor
   Northwestern University
      2014   -   NCT02281513   United States
Flash glucose monitoring system
   RenJi Hospital
      2017   -   NCT03296995   China
FLOW-mediated dilation OF THE brachial artery
   Michelle Petri M.D.,MPH
      2009   Phase 4   NCT00828178   United States
Fludarabine
   Adicet Therapeutics
      2024   Phase 1   NCT06375993   United States
   Artiva Biotherapeutics, Inc.
      2024   Phase 1   NCT06265220   United States
   AstraZeneca
      2025   Phase 1/Phase 2   NCT06897930   United States
   EdiGene Inc.
      2024   Phase 1   NCT06373991   China
   Fate Therapeutics
      2024   Phase 1   NCT06308978   United States
   Genentech, Inc.
      2025   Phase 1   NCT06984341   -
   IRIS Research and Development, LLC
      2024   Phase 1   NCT06581562   United States
   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
      2023   Phase 1   NCT05869955   Belgium;France;Germany;Italy;Spain;United States
   Miltenyi Biomedicine GmbH
      2025   Phase 1   NCT06708845   -
   New York Medical College
      2007   Phase 1   NCT00684255   United States
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 1/Phase 2   NCT02080195   United States
Fludarabine phosphate
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00076752   United States
Fluorine F 18 clofarabine
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States
Fluzone
   University of Alabama at Birmingham
      2007   -   NCT00611611   United States
Focetria
   Tel-Aviv Sourasky Medical Center
      2009   Phase 2   NCT01006681   -
Forigerimod
   Cephalon, Inc.
      2011   -   EUCTR2010-019293-32-DE   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2011   Phase 3   EUCTR2010-019293-32-BE   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-019293-32-PT   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-019293-32-CZ   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-018383-16-PT   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-018383-16-HU   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-018383-16-DE   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-018383-16-CZ   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   Phase 2   EUCTR2010-018383-16-BE   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
Fostamatinib
   Rigel Pharmaceuticals
      2008   Phase 2   NCT00752999   -
FT819
   Fate Therapeutics
      2024   Phase 1   NCT06308978   United States
Full history , clinical examination, assesment OF disease activity ,laboratory investigations ( CBC , ESR, CRP serum creatinine and blood urea, random plas
   Assiut University
      2024   -   NCT06586567   -
Fumaderm® initial
   Universitätsklinikum Münster
      2011   -   EUCTR2010-023645-29-DE   Germany
G-CSF
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00230035   United States
Gardasil
   Tuen Mun Hospital
      2009   Phase 4   NCT00911521   China
   University of Chicago
      2008   -   NCT00786409   United States
   Wayne State University
      2013   Phase 1   NCT01741012   United States
Gazyvaro
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-005760-57-IT   Argentina;Australia;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2023   Phase 3   EUCTR2020-005760-57-CZ   Argentina;Australia;Brazil;Czech Republic;Czechia;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005760-57-PL   Argentina;Australia;Brazil;Czech Republic;Czechia;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005760-57-FR   Argentina;Australia;Brazil;Czech Republic;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-005760-57-ES   Argentina;Australia;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
GB261
   Wuhan Union Hospital, China
      2025   Phase 1   NCT06945068   China
GC+HCQ
   Peking Union Medical College Hospital
      2016   -   NCT02842814   China
GC012F injection
   Gracell Biotechnologies (Shanghai) Co., Ltd.
      2024   Phase 1/Phase 2   NCT06530849   China
   Zhejiang University
      2023   Phase 1   NCT05846347   China
GDC-0853
   Genentech, Inc.
      2018   Phase 2   NCT03407482   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   NCT02908100   Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;Thailand;United Kingdom;United States
GDC-0853 RO7010939
   Genentech, Inc.
      2018   Phase 2   EUCTR2017-001764-37-PT   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001764-37-GB   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001764-37-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-001039-11-PT   Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-001039-11-ES   Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-001039-11-DE   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-001039-11-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2016   Phase 2   EUCTR2016-001039-11-GB   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
   Roche Farma, S.A por delegación de Genentech, Inc.
      2017   Phase 2   EUCTR2017-001764-37-ES   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
Genotype detection
   Sun Yat-sen University
      2012   -   NCT01689350   China
GL701
   Genelabs Technologies
      2003   Phase 3   NCT00082511   Mexico;United States
      2002   Phase 3   NCT00053560   Mexico;United States
      1998   Phase 3   NCT00037128   United States
GLPG3667
   Galapagos NV
      2023   Phase 2   NCT05856448   Argentina;Bulgaria;Chile;France;Georgia;Germany;Hungary;Peru;Poland;Puerto Rico;Spain;United States
GLPG3970 FILM-coated tablet
   Galapagos NV
      2020   Phase 1   NCT04700267   Bulgaria;Moldova, Republic of;Poland;Spain;Ukraine
Glucocorticoid
   Chinese SLE Treatment And Research Group
      2023   Phase 4   NCT05916781   China
   The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
      2017   -   ChiCTR-INC-17011497   China
   The Third Affiliated Hospital, Southern Medical University
      2018   -   ChiCTR1800019308   China
   Zhejiang Chinese Medical University
      2021   -   ChiCTR2100048796   China
GNC-038
   Sichuan Baili Pharmaceutical Co., Ltd.
      2025   Phase 1   NCT06857214   China
Group A SLE prospective study
   Oklahoma Medical Research Foundation
      2009   Phase 1/Phase 2   NCT00987831   United States
Group B SLE ONE blood donation
   Oklahoma Medical Research Foundation
      2009   Phase 1/Phase 2   NCT00987831   United States
GSK1550188
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2013   -   EUCTR2011-000368-88-IT   Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Spain;United Kingdom;United States
   GlaxoSmithKline
      2024   Phase 4   NCT06411249   Argentina;Brazil;France;Germany;Greece;Italy;Japan;Mexico;Portugal;Spain;United States
   GlaxoSmithKline Research & Development Ltd
      2020   Phase 2   EUCTR2018-004645-16-NL   Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States
      2019   Phase 2   EUCTR2018-004645-16-DE   Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States
      2018   Phase 3   EUCTR2016-003050-32-NL   Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States
      2018   Phase 3   EUCTR2016-003050-32-DE   Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States
      2012   -   EUCTR2011-000368-88-NL   Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      2012   Phase 2   EUCTR2011-000368-88-GB   Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2011-000368-88-PL   Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
      -   -   EUCTR2011-000368-88-Outside-EU/EEA   Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
   GlaxoSmithKline, S.A.
      2019   Phase 2   EUCTR2018-004645-16-ES   Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States
      2017   Phase 3   EUCTR2016-003050-32-ES   Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;South Africa;Spain;United States
      2012   -   EUCTR2011-000368-88-ES   Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States
GSK1550188 1MG/KG or 10MG/KG
   GlaxoSmithKline
      2010   Phase 1   NCT01381536   Japan
GSK1550188 IV
   GlaxoSmithKline
      2011   Phase 1   NCT01516450   Japan
GSK1550188 SC
   GlaxoSmithKline
      2011   Phase 1   NCT01516450   Japan
GSK2586184
   GlaxoSmithKline Research and Development Limited
      2013   -   EUCTR2012-001645-41-SE   Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand
      2013   -   EUCTR2012-001645-41-PL   Argentina;Brazil;Chile;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Thailand
      2013   -   EUCTR2012-001645-41-DE   Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand
      2013   -   EUCTR2012-001645-41-CZ   Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand
      2012   -   EUCTR2012-001645-41-HU   Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand
      2012   -   EUCTR2012-001645-41-GR   Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand
      2012   Phase 2   EUCTR2012-001645-41-EE   Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Korea, Republic of;Peru;Poland;South Africa;Spain;Sweden
   GlaxoSmithKline, S.A.
      2012   -   EUCTR2012-001645-41-ES   Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand
GSK2586184 100 MG
   GlaxoSmithKline
      2013   Phase 2   NCT01777256   Argentina;Brazil;Chile;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Korea, Republic of;Peru;Poland;Romania;South Africa;Spain;Sweden
GSK2586184 200 MG
   GlaxoSmithKline
      2013   Phase 2   NCT01777256   Argentina;Brazil;Chile;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Korea, Republic of;Peru;Poland;Romania;South Africa;Spain;Sweden
GSK2586184 400 MG
   GlaxoSmithKline
      2013   Phase 2   NCT01777256   Argentina;Brazil;Chile;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Korea, Republic of;Peru;Poland;Romania;South Africa;Spain;Sweden
GSK2586184 50 MG
   GlaxoSmithKline
      2013   Phase 2   NCT01777256   Argentina;Brazil;Chile;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Korea, Republic of;Peru;Poland;Romania;South Africa;Spain;Sweden
GSK2586184 800MG single and repeat dose
   GlaxoSmithKline
      2012   Phase 1   NCT01687309   Belgium
GSK2586184 NEW formulation
   GlaxoSmithKline
      2013   Phase 1   NCT01953835   United States
GSK2586184 single dose taken with food
   GlaxoSmithKline
      2012   Phase 1   NCT01687309   Belgium
GSK2586184 single dose taken without food
   GlaxoSmithKline
      2012   Phase 1   NCT01687309   Belgium
GSK2586184 standard formulation
   GlaxoSmithKline
      2013   Phase 1   NCT01953835   United States
GSK4347859
   GlaxoSmithKline
      2024   Phase 1   NCT06188507   United Kingdom
GSK4527363
   GlaxoSmithKline
      2024   Phase 1   NCT06576271   United Kingdom
Gusacitinib
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2025   Phase 1   NCT06238531   United States
H.P. acthar GEL
   Fiechtner, Justus J., M.D., P.C.
      2012   Phase 4   NCT01769937   United States
HA 1A anticorpo monoclonale umano classe IGM
   BIOGEN IDEC RESEARCH LIMITED
      2023   Phase 3   EUCTR2021-006378-22-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005776-35-IT   Argentina;Belgium;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;United Kingdom;United States
HB-admscs
   Hope Biosciences Stem Cell Research Foundation
      2023   -   NCT04907175   United States
HC022
   HC Biopharma Inc.
      2024   Phase 1   NCT06657703   China
HCQ
   Atsumi Tatsuya
      2020   Phase 4   JPRN-jRCTs011190011   -
Heart health educational program
   Brigham and Women's Hospital
      2003   Phase 2   NCT00054938   United States
Hematopoietic cell transplantation
   Stanford University
      2004   Phase 1   NCT00325741   United States
Hematopoietic stem cell transplantation
   Northwestern University
      2005   Phase 2   NCT00278538   United States
Herpes zoster subunit (HZ/SU) vaccine
   NYU Langone Health
      2023   Phase 4   NCT05559671   United States
Herpes zoster vaccine
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
HGS1006
   HUMAN GENOME SCIENCES INC
      2009   Phase 3   EUCTR2007-007648-85-IT   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-IT   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
   Human Genome Sciences, Inc
      2009   Phase 3   EUCTR2007-007648-85-SK   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
   Human Genome Sciences, Inc.
      2010   Phase 3   EUCTR2007-007648-85-AT   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
      2009   Phase 1;Phase 3   EUCTR2007-007648-85-SE   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
      2009   Phase 3   EUCTR2007-007648-85-GB   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
      2009   Phase 3   EUCTR2007-007648-85-FR   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-007648-85-ES   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-007648-85-DE   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom
      2009   Phase 3   EUCTR2007-007648-85-BE   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
      2007   Phase 3   EUCTR2006-005177-21-SK   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-SE   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-NL   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005177-21-GB   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005177-21-FR   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005177-21-ES   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-DE   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-CZ   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-BE   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-AT   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
   Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
      2009   Phase 3   EUCTR2007-007648-85-NL   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
      2009   Phase 3   EUCTR2007-007648-85-CZ   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
HGS1006, lymphostat-B, monoclonal ANTI-blys, LSB, benlysta
   GlaxoSmithKline Research & Development Ltd
      2018   Phase 3   EUCTR2016-003050-32-NL   Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States
      2018   Phase 3   EUCTR2016-003050-32-DE   Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States
   GlaxoSmithKline, S.A.
      2017   Phase 3   EUCTR2016-003050-32-ES   Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;South Africa;Spain;United States
High dietary sodium
   Vanderbilt University
      2018   -   NCT02525835   United States
High dose GR1603 IN phase?B
   Genrix (Shanghai) Biopharmaceutical Co., Ltd.
      2022   Phase 1/Phase 2   NCT06015230   China
HLL2
   Immunomedics, Inc.
      2006   Phase 3   EUCTR2005-000705-59-HU   Germany;Hungary;Italy;Slovakia;Spain;United Kingdom
      2005   -   EUCTR2005-000706-31-GB   Germany;Italy;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-000706-31-ES   Belgium;Germany;Italy;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-000705-59-SK   Germany;Hungary;Italy;Slovakia;Spain;United Kingdom
      2005   -   EUCTR2005-000705-59-GB   Germany;Hungary;Italy;Spain;United Kingdom
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2001   Phase 1   NCT00011908   United States
   UCB Inc
      2008   -   EUCTR2007-002589-37-HU   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-002589-37-GB   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   -   EUCTR2007-002589-37-ES   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   -   EUCTR2007-002566-35-LT   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   -   EUCTR2007-002566-35-HU   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   -   EUCTR2007-002566-35-GB   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-002566-35-ES   Belgium;Hungary;Lithuania;Spain;United Kingdom
      2008   -   EUCTR2007-002566-35-BE   Belgium;Hungary;Lithuania;Spain;United Kingdom
   UCB Pharma Inc.
      2006   -   EUCTR2005-000706-31-DE   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2005-000706-31-BE   Belgium;Germany;Italy;Spain;United Kingdom
   UCB Pharma, Inc
      2006   -   EUCTR2005-000705-59-DE   Germany;Hungary;Italy;Spain;United Kingdom
HLL2,IMMU-103
   IMMUNOMEDICS
      2005   -   EUCTR2005-000706-31-IT   Germany;Italy;Spain;United Kingdom
HN2301 injection
   Shenzhen MagicRNA Biotechnology Co., Ltd
      2025   -   NCT06801119   China
HPV prophylactic vaccine gardasil
   University Hospital, Bordeaux
      2012   Phase 2   NCT01687192   France
HRIL-2 active
   Peking University People's Hospital
      2015   Phase 2   NCT02465580   China
Human umbilical cord derived MSC transplantation FOR SLE
   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
      2012   Phase 1/Phase 2   NCT01741857   China
Humanised IGG1 monoclonal antibody against blood dendritic cell antigen 2
   Biogen Idec Research Limited
      2022   Phase 3   EUCTR2020-005776-35-RO   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005776-35-DE   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005776-35-BE   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005775-12-FR   Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005776-35-NL   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005776-35-HU   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005776-35-CZ   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005775-12-GR   Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States
      2021   Phase 3   EUCTR2020-005775-12-ES   Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States
Hydroxychloroquine
   Chinese SLE Treatment And Research Group
      2015   Phase 3   NCT02444728   China
   Christine Bengtsson
      2015   Phase 2   EUCTR2014-005418-45-SE   Sweden
   Department of Internal Medicine, Teikyo University School of Medicine
      2014   -   JPRN-UMIN000012478   Japan
   Fen Li
      2022   Phase 4   NCT05666336   China
   Guang'anmen Hospital, China Academy of Chinese Medical Sciences
      2023   Phase 1   ChiCTR2300073848   China
   Ishii Tomonori
      2022   -   JPRN-jRCTs021210042   -
   Milton S. Hershey Medical Center
      2017   Phase 2   NCT03030118   United States
   NYU Langone Health
      2024   Phase 3   NCT05799378   United States
   Nanjing Drum Tower Hospital
      2022   Phase 4   ChiCTR2300070628   China
   Nanjing University of Chinese Medicine Affiliated Hospital
      2019   Phase 1   ChiCTR1900022934   China
      2019   Phase 1 study   ChiCTR1800020286   China
   Renji Hospital, Shanghai JiaoTong University School of Medicine
      2012   -   ChiCTR-TRC-12002419   China
   Ruijin Hospital
      2018   Phase 4   ChiCTR1800017540   China
   Sanofi
      2012   Phase 3   NCT01551069   Japan
   Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
      2024   Phase 0   ChiCTR2400082069   China
   The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
      2017   -   ChiCTR-INR-17011495   China
   The Third Affiliated Hospital, Southern Medical University
      2018   -   ChiCTR1800019308   China
   Zhejiang Chinese Medical University
      2021   -   ChiCTR2100048796   China
      2015   -   ChiCTR-ONC-15007547   China
   the Third Xiangya Hospital of Central South University
      2020   Phase 4   ChiCTR2300067695   China
Hydroxychloroquine or chloroquine
   National Institute of Allergy and Infectious Diseases (NIAID)
      2013   Phase 2   NCT01946880   United States
Hydroxychloroquine reduced
   University of Sao Paulo General Hospital
      2017   Phase 4   NCT03122431   Brazil
HZN-7734, VIB7734, MEDI7734
   Horizon Therapeutics Ireland DAC
      2022   Phase 2   EUCTR2022-000855-35-PL   Argentina;Greece;India;Mexico;Poland;Serbia;Spain;Taiwan;United States
      2022   Phase 2   EUCTR2022-000855-35-GR   Argentina;Greece;India;Mexico;Poland;Serbia;Spain;Taiwan;United States
      2022   Phase 2   EUCTR2022-000855-35-ES   Argentina;Greece;India;Mexico;Poland;Serbia;Spain;Taiwan;United States
Ianalumab
   Maruyama Hideki
      2023   Phase 3   JPRN-jRCT2061220094   Brazil;Bulgaria;Canada;China;Czech Republic;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Singapore;Slovakia;South Africa;Spain;Thailand;Turkey;United States
   NOVARTIS PHARMA AG
      2023   Phase 3   EUCTR2022-002690-29-IT   Argentina;Australia;Chile;Colombia;France;Germany;India;Italy;Korea, Republic of;Mexico;Romania;Taiwan;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2022   Phase 3   EUCTR2022-002691-36-ES   Brazil;Bulgaria;Canada;China;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Turkey;United States
      2018   Phase 2   EUCTR2018-001508-12-ES   Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand
   Novartis Pharma AG
      2023   Phase 3   EUCTR2022-002691-36-SK   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Turkey;United States
      2023   Phase 3   EUCTR2022-002691-36-PT   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Türkiye;United States
      2023   Phase 3   EUCTR2022-002691-36-PL   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Türkiye;United States
      2023   Phase 3   EUCTR2022-002691-36-HU   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Turkey;United States
      2023   Phase 3   EUCTR2022-002691-36-CZ   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Turkey;United States
      2023   Phase 3   EUCTR2022-002691-36-BG   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Türkiye;United States
      2023   Phase 3   EUCTR2022-002690-29-RO   Argentina;Australia;Chile;Colombia;France;Germany;India;Italy;Korea, Republic of;Mexico;Romania;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002690-29-FR   Argentina;Australia;Chile;Colombia;France;Germany;India;Italy;Korea, Republic of;Mexico;Romania;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002690-29-DE   Argentina;Australia;Chile;France;Germany;India;Italy;Korea, Republic of;Mexico;Romania;South Africa;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001508-12-FR   Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand
      2018   Phase 2   EUCTR2018-001508-12-DE   Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States
      2018   Phase 2   EUCTR2018-001508-12-CZ   Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States
   Novartis Pharmaceuticals
      2024   Phase 1   NCT06411639   -
      2024   Phase 3   NCT06133972   Argentina;Australia;Brazil;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Guatemala;Hungary;India;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Portugal;Romania;Spain;Taiwan;Thailand;United States
      2023   Phase 3   NCT05639114   Brazil;Bulgaria;Canada;China;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Singapore;Slovakia;South Africa;Spain;Thailand;Turkey;United States
      2023   Phase 3   NCT05624749   Argentina;Australia;Chile;Colombia;France;Germany;India;Italy;Korea, Republic of;Malaysia;Mexico;Romania;Taiwan;United Kingdom;United States
Ibandronate+alfacalcidol+calcium
   Chinese University of Hong Kong
      2007   Phase 4   NCT00668330   China
ICP-022
   Beijing InnoCare Pharma Tech Co., Ltd.
      2020   Phase 1/Phase 2   NCT04305197   China
   Innocare Pharma Australia Pty Ltd
      2017   Phase 1   NCT03189017   Australia
IFN-A 2B kinoid drug substance
   Neovacs SA
      2010   Phase 1;Phase 2   EUCTR2009-012059-47-FR   Belgium;Bulgaria;France;Germany
      2010   Phase 1;Phase 2   EUCTR2009-012059-47-DE   Belgium;Bulgaria;France;Germany
      2010   Phase 1;Phase 2   EUCTR2009-012059-47-BG   Belgium;Bulgaria;France;Germany
      2010   Phase 1;Phase 2   EUCTR2009-012059-47-BE   Belgium;Bulgaria;France;Germany
IFN-A2B kinoid
   Neovacs SA
      2010   Phase 1;Phase 2   EUCTR2009-012059-47-FR   Belgium;Bulgaria;France;Germany
      2010   Phase 1;Phase 2   EUCTR2009-012059-47-DE   Belgium;Bulgaria;France;Germany
      2010   Phase 1;Phase 2   EUCTR2009-012059-47-BG   Belgium;Bulgaria;France;Germany
      2010   Phase 1;Phase 2   EUCTR2009-012059-47-BE   Belgium;Bulgaria;France;Germany
IFN-K
   NEOVACS
      2015   Phase 2   EUCTR2015-001341-86-IT   Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;Peru;Philippines;Poland;Russian Federation;Spain;Taiwan;Thailand;United States
   Neovacs
      2010   Phase 1/Phase 2   NCT01058343   Belgium;Bulgaria;Croatia;France;Germany;Romania;Spain;Switzerland
   Neovacs S.A.
      2017   Phase 2   EUCTR2015-001341-86-ES   Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States
      2017   Phase 2   EUCTR2015-001341-86-BG   Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States
      2015   Phase 2   EUCTR2015-001341-86-DE   Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States
      2015   Phase 2   EUCTR2015-001341-86-BE   Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States
   Neovacs SA
      2010   Phase 1;Phase 2   EUCTR2009-012059-47-FR   Belgium;Bulgaria;France;Germany
      2010   Phase 1;Phase 2   EUCTR2009-012059-47-DE   Belgium;Bulgaria;France;Germany
      2010   Phase 1;Phase 2   EUCTR2009-012059-47-BG   Belgium;Bulgaria;France;Germany
      2010   Phase 1;Phase 2   EUCTR2009-012059-47-BE   Belgium;Bulgaria;France;Germany
   Neovas S.A.
      2015   Phase 2   EUCTR2015-001341-86-HR   Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;Peru;Philippines;Poland;Russian Federation;Spain;Switzerland;Taiwan;Thailand;United States
IFN-kinoid
   NEOVACS
      2015   Phase 2   EUCTR2015-001341-86-IT   Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;Peru;Philippines;Poland;Russian Federation;Spain;Taiwan;Thailand;United States
IFN-kinoid drug substance
   Neovacs S.A.
      2017   Phase 2   EUCTR2015-001341-86-ES   Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States
      2017   Phase 2   EUCTR2015-001341-86-BG   Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States
      2015   Phase 2   EUCTR2015-001341-86-DE   Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States
      2015   Phase 2   EUCTR2015-001341-86-BE   Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States
   Neovas S.A.
      2015   Phase 2   EUCTR2015-001341-86-HR   Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;Peru;Philippines;Poland;Russian Federation;Spain;Switzerland;Taiwan;Thailand;United States
IFNA-kinoid
   Neovacs
      2015   Phase 2   NCT02665364   Argentina;Belgium;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Switzerland;Taiwan;Thailand;Tunisia;United States
Iguratimod
   the Third Xiangya Hospital of Central South University
      2020   Phase 4   ChiCTR2300067695   China
IL-2
   Century Therapeutics, Inc.
      2025   Phase 1   NCT06255028   United States
   the Second Hospital of Shanxi Medical University
      2016   -   ChiCTR-IPR-16009451   China
IL-6
   the Second Hospital of Shanxi Medical University
      2016   -   ChiCTR-IPR-16009451   China
IL-6R nanobody
   Ablynx N.V.
      2015   Phase 2   EUCTR2015-000372-95-PT   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2015   Phase 2   EUCTR2015-000372-95-HU   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2015   Phase 2   EUCTR2015-000372-95-ES   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2015   Phase 2   EUCTR2015-000372-95-DE   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2015   Phase 2   EUCTR2015-000372-95-CZ   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
ILT-101
   ILTOO PHARMA
      2018   Phase 2   EUCTR2016-000488-17-FR   Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain
      2017   Phase 2   EUCTR2016-000488-17-IT   Austria;Bulgaria;France;Italy;Portugal;Spain
      2017   Phase 2   EUCTR2016-000488-17-BG   Austria;Bulgaria;France;Germany;Italy;Mexico;Portugal;Romania;Spain
      2016   Phase 2   EUCTR2016-000488-17-PT   Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain
      2016   Phase 2   EUCTR2016-000488-17-ES   Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain
      2016   Phase 2   EUCTR2016-000488-17-AT   Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain
   Iltoo Pharma
      2017   Phase 2   NCT02955615   Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain
IM19 CAR-T cells
   Peking University Third Hospital
      2024   -   NCT06513429   China
IMC-002 + SOC
   ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
      2024   Phase 1/Phase 2   NCT06535412   -
IMMU-103
   Immunomedics, Inc.
      2006   Phase 3   EUCTR2005-000705-59-HU   Germany;Hungary;Italy;Slovakia;Spain;United Kingdom
      2005   -   EUCTR2005-000706-31-GB   Germany;Italy;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-000706-31-ES   Belgium;Germany;Italy;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-000705-59-SK   Germany;Hungary;Italy;Slovakia;Spain;United Kingdom
      2005   -   EUCTR2005-000705-59-GB   Germany;Hungary;Italy;Spain;United Kingdom
   UCB Pharma Inc.
      2006   -   EUCTR2005-000706-31-DE   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2005-000706-31-BE   Belgium;Germany;Italy;Spain;United Kingdom
   UCB Pharma, Inc
      2006   -   EUCTR2005-000705-59-DE   Germany;Hungary;Italy;Spain;United Kingdom
Immunoglobulin G
   Boston Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2018-000305-23-RO   Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States
      2019   Phase 2   EUCTR2018-000305-23-HU   Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States
      2019   Phase 2   EUCTR2018-000305-23-BG   Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States
Immunoglobulin G1, ANTI-(human type I interferon receptor) (human monoclonal MEDI-546 heavy chain), disulfide with human monoclonal MEDI-546-chain, dimer
   Astrazeneca AB
      2017   Phase 2   EUCTR2016-003246-93-PL   Hungary;Korea, Republic of;Poland;United States
Immunologic technique
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00076752   United States
IMPT-514
   Lyell Immunopharma, Inc.
      2024   Phase 1/Phase 2   NCT06153095   Australia;United States
IMPT-514 cart cell injection
   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
      2024   Early Phase 1   NCT06462144   China
Imvotamab
   IGM Biosciences, Inc.
      2023   Phase 1   NCT06041568   Korea, Republic of;Poland;United States
Inaticabtagene autoleucel injection
   Juventas Cell Therapy Ltd.
      2025   Phase 1   NCT06826430   -
Individualized dose OF rituximab
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   Phase 4   NCT04127747   China
Inebilizumab
   Amgen
      2025   Phase 2   NCT06570798   Belgium;France;Germany;Italy;United States
Infliximab
   Department of Rheumatology, Internal Medicine III, Medical University of Vienna
      2006   -   EUCTR2005-004067-30-NL   Austria;Germany;Netherlands
      2006   -   EUCTR2005-004067-30-DE   Austria;Germany;Netherlands
      2006   -   EUCTR2005-004067-30-AT   Austria;Germany;Netherlands
   Medical University of Vienna
      2006   Phase 2/Phase 3   NCT00368264   Austria;Germany;Netherlands
Influenz virus surface antigens
   University Medical Center Groningen
      2007   -   EUCTR2007-004579-21-NL   Netherlands
Influvac
   University Medical Center Groningen
      2007   -   EUCTR2007-004579-21-NL   Netherlands
Interleukin 2
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 2   NCT01988506   France
Interleukin 23
   Sohag University
      2025   -   NCT06713187   Egypt
Interleukin-2
   ILTOO PHARMA
      2018   Phase 2   EUCTR2016-000488-17-FR   Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain
      2017   Phase 2   EUCTR2016-000488-17-BG   Austria;Bulgaria;France;Germany;Italy;Mexico;Portugal;Romania;Spain
      2016   Phase 2   EUCTR2016-000488-17-PT   Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain
      2016   Phase 2   EUCTR2016-000488-17-ES   Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain
      2016   Phase 2   EUCTR2016-000488-17-AT   Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain
   Liu Tian
      2023   Phase 3   NCT05339217   China
   Peking University People's Hospital
      2022   Phase 3   NCT05262686   China
      2019   Phase 2   NCT04077684   China
      2016   -   NCT02932137   China
      2013   -   NCT02084238   China
Intravenous immunoglobulin
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00230035   United States
IPP - 201101
   IMMUPHARMA SA
      2008   -   EUCTR2007-004892-21-BG   Bulgaria;Spain
IPP-201101
   IMMUPHARMA
      2016   Phase 3   EUCTR2015-003341-25-IT   France;Germany;Hungary;Italy;United Kingdom
   IMMUPHARMA SA
      2008   -   EUCTR2007-004892-21-BG   Bulgaria;Spain
   ImmuPharma
      2018   Phase 3   NCT03427151   Czechia;France;Germany;Hungary;Mauritius;Poland;Puerto Rico;United States
      2018   Phase 3   EUCTR2017-004060-35-HU   Hungary;Mauritius;United States
      2015   Phase 3   NCT02504645   Czech Republic;Czechia;France;Germany;Hungary;Italy;Mauritius;Poland;Puerto Rico;United States
   ImmuPharma SA
      2016   Phase 3   EUCTR2015-003341-25-HU   France;Germany;Hungary;United States
      2016   Phase 3   EUCTR2015-003341-25-GB   France;Germany;Hungary;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003341-25-FR   France;Germany;Hungary;United States
      2016   Phase 3   EUCTR2015-003341-25-DE   France;Germany;Hungary;United Kingdom;United States
IPP-201101, P140
   Cephalon, Inc.
      2011   -   EUCTR2010-019293-32-DE   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2011   Phase 3   EUCTR2010-019293-32-BE   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-019293-32-PT   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-019293-32-HU   Czech Republic;Hungary;Portugal;Spain
      2010   Phase 3   EUCTR2010-019293-32-ES   Belgium;Czech Republic;Germany;Hungary;Portugal;Spain
      2010   -   EUCTR2010-019293-32-CZ   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-018383-16-PT   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-018383-16-HU   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   Phase 2   EUCTR2010-018383-16-FR   Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain
      2010   Phase 2   EUCTR2010-018383-16-ES   Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain
      2010   -   EUCTR2010-018383-16-DE   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-018383-16-CZ   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   Phase 2   EUCTR2010-018383-16-BE   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
ISA 51 VG
   Neovacs
      2015   Phase 2   NCT02665364   Argentina;Belgium;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Switzerland;Taiwan;Thailand;Tunisia;United States
Iscalimab
   Novartis Farmacéutica, S.A.
      2018   Phase 2   EUCTR2018-001508-12-ES   Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand
   Novartis Pharma AG
      2019   Phase 2   EUCTR2018-001508-12-FR   Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand
      2018   Phase 2   EUCTR2018-001508-12-DE   Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States
      2018   Phase 2   EUCTR2018-001508-12-CZ   Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States
Isoniazid/pyridoxine
   Universitas Padjadjaran
      2022   Phase 2/Phase 3   NCT06618573   Indonesia
Itolizumab
   Equillium
      2019   Phase 1   NCT04128579   India;Poland;United States
JBT-101
   National Institute of Allergy and Infectious Diseases (NIAID)
      2017   Phase 2   NCT03093402   United States
JMKX000189
   Jemincare
      2023   Phase 2   NCT05967520   China
JNJ-54767414
   Charité - Universitätsmedizin Berlin
      2021   Phase 2   EUCTR2021-000962-14-DE   Germany
JNJ-55920839
   Janssen Research & Development, LLC
      2015   Phase 1   NCT02609789   Belgium;Moldova, Republic of;Poland;Romania;Spain;Taiwan;United States
JNJ-56022473
   Janssen Research & Development, LLC
      2017   Phase 1   NCT02920424   Germany
JNJ-80202135
   Janssen-Cilag International NV
      2021   Phase 2   EUCTR2020-005569-14-PL   Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States
      2021   Phase 2   EUCTR2020-005569-14-HU   Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States
      2021   Phase 2   EUCTR2020-005569-14-ES   Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States
      2021   Phase 2   EUCTR2020-005569-14-BG   Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States
JY231 injection
   920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
      2024   Phase 1/Phase 2   NCT06675422   China
Ketogenic diet
   Chang Gung Memorial Hospital
      2022   -   NCT05689580   Taiwan
Kineret
   Dr Josep Ordi Ros
      2012   Phase 2   EUCTR2011-005392-16-ES   Spain
KK4277
   Kyowa Kirin Co., Ltd.
      2022   Phase 1   NCT05411016   Japan;Korea, Republic of
KP104
   Kira Pharmacenticals (US), LLC.
      2025   Phase 2   NCT05504187   -
KPG-818
   Kangpu Biopharmaceuticals, Ltd.
      2019   Phase 1   NCT03949426   United States
KPG-818 high dose
   Kangpu Biopharmaceuticals, Ltd.
      2021   Phase 1/Phase 2   NCT04643067   United States
KPG-818 LOW dose
   Kangpu Biopharmaceuticals, Ltd.
      2021   Phase 1/Phase 2   NCT04643067   United States
KPG-818 MID dose
   Kangpu Biopharmaceuticals, Ltd.
      2021   Phase 1/Phase 2   NCT04643067   United States
KZR-616
   Kezar Life Sciences, Inc.
      2018   Phase 1/Phase 2   NCT03393013   Australia;Colombia;Mexico;Peru;Poland;Russian Federation;Ukraine;United States
L04aa26
   GlaxoSmithKline, LLC
      2013   Phase 4   EUCTR2011-005667-25-PT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-LT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-CZ   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
   Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
      2014   Phase 4   EUCTR2011-005667-25-PL   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-SK   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-RO   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-ES   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
      2013   Phase 4   EUCTR2011-005667-25-EE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States
   Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
      2013   Phase 3;Phase 4   EUCTR2011-005672-42-GB   Brazil;Colombia;France;Martinique;South Africa;United Kingdom;United States
LA294
   Eli Lilly and Company
      2014   -   EUCTR2010-022101-18-HR   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2013   -   EUCTR2010-022101-18-DE   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-LV   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-HU   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-GB   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-ES   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-BG   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-AT   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2010-022100-42-LV   Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States
      2011   -   EUCTR2010-022100-42-HU   Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States
      2011   Phase 3   EUCTR2010-022100-42-GB   Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States
      2011   -   EUCTR2010-022099-29-DE   Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States
      2011   -   EUCTR2010-022099-29-BG   Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States
      2011   -   EUCTR2010-022099-29-AT   Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States
Laboratory biomarker analysis
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00076752   United States
Lacteol forte capsules
   Ain Shams University
      2022   Phase 2   NCT05433857   Egypt
Laquinimod
   Teva Branded Pharmaceutical Products R&D, Inc.
      2010   Phase 2   NCT01085097   Canada;France;Russian Federation;United Kingdom;United States
      2010   Phase 2   NCT01085084   Canada;United States
LCAR-AIO T cells
   Wuhan Union Hospital, China
      2025   Early Phase 1   NCT06653556   China
Leflunomide
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00230035   United States
   Sanofi
      2003   Phase 2   NCT00637819   Hong Kong
   The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
      2017   -   ChiCTR-INR-17011495   China
Lenalidomide
   Chinese Academy of Medical Sciences Peking Union Medical College Hospital
      2019   Phase 4   ChiCTR1900025376   China
Leukapheresis
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00230035   United States
Levothyroxine
   Johns Hopkins University
      2011   Phase 4   NCT01276782   United States
Lisinopril pills
   Northwell Health
      2021   Phase 2   NCT04486118   United States
Litifilimab
   Biogen
      2022   Phase 3   NCT05352919   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2021   Phase 3   NCT04961567   Argentina;Belgium;Bulgaria;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Puerto Rico;Romania;Serbia;United Kingdom;United States
      2021   Phase 3   NCT04895241   Australia;Brazil;Bulgaria;Chile;China;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States
      2014   Phase 1   NCT02106897   United States
   Biogen Idec Research Limited
      2023   Phase 3   EUCTR2021-006378-22-RO   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2021-006378-22-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2021-006378-22-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2021-006378-22-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-006378-22-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-006378-22-CZ   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-006378-22-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Romania;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005776-35-DE   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005776-35-BE   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005776-35-CZ   Argentina;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005775-12-GR   Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States
LJP 394
   LA JOLLA PHARMACEUTICAL COMPANY
      2008   -   EUCTR2006-000674-73-IT   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
   La Jolla Pharmaceutical Company
      2008   -   EUCTR2006-000674-73-PT   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
      2008   -   EUCTR2006-000674-73-ES   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
      2008   -   EUCTR2006-000674-73-DE   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
      2008   -   EUCTR2006-000674-73-CZ   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
      2008   -   EUCTR2006-000674-73-BG   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
      2006   Phase 2   NCT00390091   United States
      2006   Phase 3   EUCTR2006-000674-73-SK   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Slovakia;Spain
      2006   -   EUCTR2006-000674-73-HU   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
      2004   Phase 3   NCT00089804   Argentina;Australia;Belarus;Brazil;Bulgaria;Czech Republic;Former Serbia and Montenegro;Georgia;Germany;Hong Kong;Hungary;India;Indonesia;Italy;Korea, Republic of;Lebanon;Malaysia;Mexico;Philippines;Poland;Portugal;Puerto Rico;Romania;Serbia;Slovakia;Spain;Sri Lanka;Taiwan;Thailand;Ukraine;United States
      2001   Phase 3   NCT00035308   Austria;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
LJP394
   AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
      2009   -   EUCTR2008-004852-62-IT   Italy
   La Jolla Pharmaceutical Company
      2008   -   EUCTR2006-000674-73-BG   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
LMY-920
   Luminary Therapeutics
      2025   Phase 1   NCT06340750   United States
LOW dietary sodium
   Vanderbilt University
      2018   -   NCT02525835   United States
LOW dose GR1603 IN phase ?B
   Genrix (Shanghai) Biopharmaceutical Co., Ltd.
      2022   Phase 1/Phase 2   NCT06015230   China
Lulizumab pegol
   Bristol-Myers Squibb International Corporation
      2015   Phase 2   EUCTR2014-002184-14-NL   Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-002184-14-IT   Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-002184-14-DE   Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States
   Bristol-Myers Squibb K.K.
      2015   Phase 2   JPRN-jRCT2080223023   Asia except Japan;Europe;Japan;North America;South America
Lupus impact tracker questionnaire
   Hospices Civils de Lyon
      2024   Phase 2   NCT06356740   France
Lupuzor
   Cephalon
      2010   Phase 2   NCT01135459   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United Kingdom;United States
   Cephalon, Inc.
      2011   -   EUCTR2010-019293-32-DE   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2011   Phase 3   EUCTR2010-019293-32-BE   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-019293-32-PT   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-019293-32-HU   Czech Republic;Hungary;Portugal;Spain
      2010   Phase 3   EUCTR2010-019293-32-ES   Belgium;Czech Republic;Germany;Hungary;Portugal;Spain
      2010   -   EUCTR2010-019293-32-CZ   Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-018383-16-PT   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-018383-16-HU   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   Phase 2   EUCTR2010-018383-16-FR   Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain
      2010   Phase 2   EUCTR2010-018383-16-ES   Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain
      2010   -   EUCTR2010-018383-16-DE   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   -   EUCTR2010-018383-16-CZ   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
      2010   Phase 2   EUCTR2010-018383-16-BE   Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States
LY2127399
   ELI LILLY
      2011   -   EUCTR2010-022099-29-IT   Austria;Bulgaria;Germany;Italy
   ELI LILLY AND COMPANY
      2013   -   EUCTR2010-022101-18-IT   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
   Eli Lilly and Company
      2014   -   EUCTR2010-022101-18-HR   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2013   -   EUCTR2010-022101-18-DE   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   Phase 3   NCT01488708   United States
      2012   -   EUCTR2010-022101-18-LV   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-HU   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-GB   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-ES   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-BG   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2012   -   EUCTR2010-022101-18-AT   Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   NCT01205438   Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States
      2011   -   EUCTR2010-022100-42-LV   Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States
      2011   -   EUCTR2010-022100-42-HU   Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States
      2011   Phase 3   EUCTR2010-022100-42-GB   Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States
      2011   -   EUCTR2010-022100-42-ES   Hungary;Latvia;Spain;United Kingdom
      2011   -   EUCTR2010-022099-29-DE   Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States
      2011   -   EUCTR2010-022099-29-BG   Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States
      2011   -   EUCTR2010-022099-29-AT   Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States
      2010   Phase 3   NCT01196091   Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, The Former Yugoslav Republic of;Peru;Philippines;Poland;Puerto Rico;Singapore;Thailand;Turkey;Ukraine;United States
LY3009104
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 3   EUCTR2017-005028-11-IT   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005027-25-IT   Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States
   Eli Lilly Japan K.K.
      2018   Phase 3   JPRN-jRCT2080224034   Africa;Asia except Japan;Europe;Japan;North America;South America
   Eli Lilly and Company
      2020   Phase 3   EUCTR2017-005028-11-NL   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2017-005028-11-HR   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2017-005028-11-GR   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-RO   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-PL   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-HU   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-GB   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Czech Republic;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-ES   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-DE   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-CZ   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-AT   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005027-25-PL   Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States
      2019   Phase 3   EUCTR2017-005026-37-NL   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Czechia;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005026-37-HR   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005026-37-GR   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005026-37-GB   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005027-25-ES   Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States
      2018   Phase 3   EUCTR2017-005026-37-HU   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005026-37-CZ   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005026-37-BE   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005026-37-AT   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Czechia;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004404-35-RO   Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United States
      2016   Phase 2   EUCTR2015-004404-35-PL   Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004404-35-FR   Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004404-35-AT   Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United States
   Lilly S.A.
      2016   Phase 2   EUCTR2015-004404-35-ES   Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United States
LY3361237
   Eli Lilly and Company
      2022   Phase 2   NCT05123586   Argentina;Czechia;France;Mexico;Poland;Puerto Rico;Russian Federation;Taiwan;Ukraine;United States
      2022   Phase 2   EUCTR2021-001406-30-PL   Argentina;Czechia;Mexico;Poland;Puerto Rico;Russian Federation;Ukraine;United States
      2019   Phase 1   NCT03933943   United States
LY3471851
   Eli Lilly & Company
      2021   Phase 2   EUCTR2019-003323-38-DE   Argentina;Australia;Canada;Czech Republic;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003323-38-RO   Argentina;Australia;Canada;Czechia;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003323-38-PL   Argentina;Australia;Canada;Czechia;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003323-38-HU   Argentina;Australia;Canada;Czech Republic;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003323-38-GB   Argentina;Australia;Canada;Czech Republic;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
   Nektar Therapeutics
      2020   Phase 2   NCT04433585   Argentina;Australia;Canada;Czechia;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 1   NCT03556007   United States
Lymphodepleting chemotherapy
   Century Therapeutics, Inc.
      2025   Phase 1   NCT06255028   United States
Lymphostat-B
   GlaxoSmithKline Research & Development Ltd
      2020   Phase 2   EUCTR2018-004645-16-NL   Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States
      2019   Phase 2   EUCTR2018-004645-16-DE   Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States
   GlaxoSmithKline, S.A.
      2019   Phase 2   EUCTR2018-004645-16-ES   Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States
   Human Genome Sciences, Inc
      2009   Phase 3   EUCTR2007-007648-85-SK   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
   Human Genome Sciences, Inc.
      2010   Phase 3   EUCTR2007-007648-85-AT   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
      2009   Phase 1;Phase 3   EUCTR2007-007648-85-SE   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
      2009   Phase 3   EUCTR2007-007648-85-GB   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
      2009   Phase 3   EUCTR2007-007648-85-FR   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-007648-85-ES   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-007648-85-DE   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom
      2009   Phase 3   EUCTR2007-007648-85-BE   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
   Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
      2009   Phase 3   EUCTR2007-007648-85-NL   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
      2009   Phase 3   EUCTR2007-007648-85-CZ   Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
Lymphostat-B (LSB), monoclonal ANTI-blys, LSB
   GlaxoSmithKline Research & Development Limited
      -   Phase 4   EUCTR2025-000106-42-Outside-EU/EEA   China
Lymphostat-B TM
   Human Genome Sciences, Inc.
      2007   Phase 3   EUCTR2006-005177-21-SK   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-SE   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-NL   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005177-21-GB   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005177-21-FR   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005177-21-ES   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-DE   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-CZ   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-BE   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005177-21-AT   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
M281
   Janssen-Cilag International NV
      2021   Phase 2   EUCTR2020-005569-14-PL   Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States
      2021   Phase 2   EUCTR2020-005569-14-HU   Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States
      2021   Phase 2   EUCTR2020-005569-14-ES   Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States
      2021   Phase 2   EUCTR2020-005569-14-BG   Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States
M2951
   EMD Serono Research & Development Institute, Inc.
      2017   Phase 2   NCT02975336   Argentina;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States
   Merck Biopharma Co., Ltd
      2017   Phase 2   JPRN-jRCT2080223900   Africa;Asia except Japan;Europe;Japan;North America;South America
   Merck KGaA
      2017   Phase 2   EUCTR2016-002950-19-PL   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States
      2017   Phase 2   EUCTR2016-002950-19-DE   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States
      2017   Phase 2   EUCTR2016-002950-19-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States
M5049
   Merck Healthcare KGaA
      2023   Phase 2   EUCTR2022-000239-21-RO   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
      2022   Phase 2   EUCTR2022-000239-21-ES   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United States
      2022   Phase 2   EUCTR2022-000239-21-BG   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
      2022   Phase 2   EUCTR2021-004648-27-RO   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Sweden;Taiwan;United States
      2022   Phase 2   EUCTR2021-004648-27-ES   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Hungary;Japan;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States
      2022   Phase 2   EUCTR2021-004648-27-BG   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
      2020   Phase 1   NCT04647708   Bulgaria;Germany;Moldova, Republic of;North Macedonia;Spain;Ukraine
M5049 high dose
   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
      2022   Phase 2   NCT05540327   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
M5049 LOW dose
   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
      2022   Phase 2   NCT05540327   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
M5049 medium dose
   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
      2022   Phase 2   NCT05540327   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
M5049 very high dose
   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
      2022   Phase 2   NCT05540327   Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Greece;Israel;Japan;Korea, Republic of;Mauritius;Mexico;Moldova, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;Taiwan;United States
MB-CART19.1
   Miltenyi Biomedicine GmbH
      2024   Phase 1/Phase 2   NCT06189157   Germany
      2023   Phase 1;Phase 2   EUCTR2022-003137-19-DE   Germany
MC-1-50
   Chongqing Precision Biotech Co., Ltd
      2025   Phase 1   NCT06892145   China
Medi 545
   MedImmune LLC
      2007   Phase 1   NCT00482989   Argentina;Brazil;Canada;Chile;United States
      2006   Phase 1   NCT00299819   Canada;United States
MEDI-545
   ASTRAZENECA
      2011   -   EUCTR2010-024069-30-IT   Argentina;Brazil;Bulgaria;Canada;Chile;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;South Africa;Spain;Thailand;United Kingdom;United States
   AstraZeneca AB
      2012   -   EUCTR2010-024069-30-BG   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
      2011   Phase 2   EUCTR2010-024069-30-NL   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
      2011   Phase 2   EUCTR2010-024069-30-GB   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
      2011   -   EUCTR2010-024069-30-ES   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
      2011   -   EUCTR2010-024069-30-DE   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
      -   -   EUCTR2010-024069-30-HU   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
   MedImmune LLC
      2008   Phase 2   NCT00657189   United States
      2006   Phase 1   NCT00299819   Canada;United States
MEDI-545 600
   AstraZeneca
      2009   Phase 2   NCT01031836   Japan
MEDI-546
   AstraZeneca
      2022   Phase 3   EUCTR2020-004529-22-DE   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Thailand;Ukraine;United Kingdom;United States
      2021   Phase 3   NCT04877691   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Thailand;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004529-22-HU   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Thailand;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004529-22-BG   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Thailand;Ukraine;United Kingdom;United States
      2012   Phase 2   NCT01559090   Japan
   AstraZeneca AB
      2017   Phase 3   EUCTR2016-000625-39-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000625-39-LT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000625-39-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000625-39-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000625-39-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States
      2015   Phase 3   EUCTR2014-004632-19-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States
   Astrazeneca AB
      2016   Phase 2   EUCTR2016-003246-93-HU   Hungary;Korea, Republic of;Poland;United States
   MedImmune, LLC, a wholly owned subsidiary of AstraZeneca
      2014   Phase 2   EUCTR2012-004619-30-BG   Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States
      2013   Phase 2   EUCTR2012-004619-30-HU   Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States
      2013   Phase 2   EUCTR2012-004619-30-CZ   Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States
MEDI-570 0.03 MG
   MedImmune LLC
      2010   Phase 1   NCT01127321   Canada;Mexico;Peru;South Africa;United States
MEDI-570 0.1 MG
   MedImmune LLC
      2010   Phase 1   NCT01127321   Canada;Mexico;Peru;South Africa;United States
MEDI-570 0.3 MG
   MedImmune LLC
      2010   Phase 1   NCT01127321   Canada;Mexico;Peru;South Africa;United States
MEDI-570 1 MG
   MedImmune LLC
      2010   Phase 1   NCT01127321   Canada;Mexico;Peru;South Africa;United States
Medroxyprogesterone
   National Center for Research Resources (NCRR)
      2000   -   NCT00006133   United States
Melatonin
   Chinese Academy of Medical Sciences Peking Union Medical College Hospital
      2019   Phase 4   ChiCTR1900020803   China
Memantine
   Johns Hopkins University
      2006   -   NCT00181298   United States
   Vanderbilt University Medical Center
      2018   Phase 2   NCT03527472   United States
Mesenchymal stem cells
   Assistance Publique - Hôpitaux de Paris
      2019   Phase 1/Phase 2   NCT03562065   France
   Hebei Medical University
      2017   Early Phase 1   NCT03219801   China
   Medical University of South Carolina
      2018   Phase 2   NCT02633163   United States
      2017   Phase 1   NCT03171194   United States
   National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
      2025   Phase 1/Phase 2   NCT06888973   Pakistan
Mesna
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00076752   United States
Metabolically armed CD19 CAR-T cells
   Zhejiang University
      2025   Early Phase 1   NCT06711146   China
Metformin
   RenJi Hospital
      2016   Phase 4   NCT02741960   China
   Renji Hospital, Shanghai JiaoTong University School of Medicine
      2012   -   ChiCTR-TRC-12002419   China
   The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
      2017   -   ChiCTR-INC-17011497   China
Methotrexate
   Genentech, Inc.
      2007   Phase 3   NCT00539838   United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00230035   United States
   The Third Affiliated Hospital, Southern Medical University
      2018   -   ChiCTR1800019308   China
   Zhejiang Chinese Medical University
      2021   -   ChiCTR2100048796   China
      2015   -   ChiCTR-ONC-15007547   China
Methotrexate and folic acid
   University Health Network, Toronto
      1995   Phase 3   NCT00470522   Canada
Methyl prednisolone
   Imperial College London
      2015   Phase 3   NCT01773616   United Kingdom
Methylprednisolone
   Chinese SLE Treatment And Research Group
      2015   Phase 3   NCT02444728   China
   Fairview University Medical Center
      2000   -   NCT00006055   United States
   Fen Li
      2022   Phase 4   NCT05666336   China
   Genentech, Inc.
      2007   Phase 3   NCT00539838   United States
      2006   Phase 3   NCT00381810   United States
   Hoffmann-La Roche
      2021   Phase 3   NCT04963296   Argentina;Brazil;Czechia;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
   ISTITUTO GIANNINA GASLINI
      2006   Phase 3   EUCTR2005-003957-28-IT   Belgium;Denmark;Italy
   Japanese Study Group of Renal Disease in Children(JSRDC)
      2006   -   JPRN-C000000159   Japan
      1995   -   JPRN-C000000378   Japan
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00076752   United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00230035   United States
   Oklahoma Medical Research Foundation
      2017   Phase 2   NCT03355482   United States
   Teva Branded Pharmaceutical Products R&D, Inc.
      2010   Phase 2   NCT01085097   Canada;France;Russian Federation;United Kingdom;United States
   The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
      2017   -   ChiCTR-INR-17011495   China
   University of Leeds
      2017   Phase 2   NCT03054259   United Kingdom
   University of Sao Paulo General Hospital
      2018   -   NCT03492255   Brazil
Methylprednisolone sodium succinate
   University Hospital Gent
      -   Phase 3   EUCTR2005-003957-28-BE   Belgium;Denmark;Italy
MHS552
   Novartis Pharmaceuticals
      2022   Phase 1   NCT05203419   Germany
Micofenolato mofetile
   A.S.L. TO 2
      2022   Phase 3   EUCTR2021-006544-26-IT   Italy
Micofenolico acido
   Manuel Praga Terente
      2010   -   EUCTR2009-017273-38-ES   Spain
MIL62
   Beijing Mabworks Biotech Co., Ltd.
      2023   Phase 2/Phase 3   NCT05796206   China
Milatuzumab
   Gilead Sciences
      2007   Phase 1   NCT01845740   United States
Milnacipran
   Loma Linda University
      2011   Phase 4   NCT01359826   United States
Mizoribine
   Japanese Study Group of Renal Disease in Children(JSRDC)
      2006   -   JPRN-C000000159   Japan
      1995   -   JPRN-C000000378   Japan
MK-6194
   Merck Sharp & Dohme LLC
      2023   Phase 2   NCT06161116   Argentina;Brazil;Canada;Chile;China;Colombia;France;Guatemala;Italy;Japan;Malaysia;Mexico;Philippines;Poland;Spain;Turkey;United States
MMF
   Atsumi Tatsuya
      2020   Phase 4   JPRN-jRCTs011190011   -
   Bristol-Myers Squibb
      2007   Phase 2/Phase 3   NCT00430677   Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2008   Phase 2;Phase 3   EUCTR2005-004575-37-GB   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-FR   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-BE   Belgium;France;United Kingdom
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
MMF discontinuation
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MMF maintain
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Modafinil
   Hospital for Special Surgery, New York
      2006   -   NCT00297284   United States
Moderna MRNA-1273, bivalent
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
Monovalent [B.1.351] COV2 pres DTM-AS03
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
Mosunetuzumab
   Hoffmann-La Roche
      2022   Phase 1   NCT05155345   Georgia;Moldova, Republic of;Poland;Ukraine;United States
Moxifloxacin
   Bristol-Myers Squibb
      2018   Phase 1   NCT03541564   United States
MPA
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
MRA 003 US
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00046774   United States
MRI, venipuncture
   NYU Langone Health
      2002   Phase 2   NCT00412841   United States
Mrna COVD19 vaccine
   Mayo Clinic
      2021   Early Phase 1   NCT04839315   United States
MSC treatment
   Universidad de los Andes, Chile
      2019   Phase 2   NCT03917797   Chile
MSC2364447C
   EMD Serono Research & Development Institute, Inc.
      2015   Phase 1   NCT02537028   Bulgaria;United States
MT-1303 high dose
   Mitsubishi Tanabe Pharma Corporation
      2015   Phase 1   NCT02307643   Japan
MT-1303 LOW dose
   Mitsubishi Tanabe Pharma Corporation
      2015   Phase 1   NCT02307643   Japan
MTX
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
MTX discontinuation
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MTX maintain
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Multivitamin
   Chinese University of Hong Kong
      2008   Phase 4   NCT00508898   Hong Kong
Mycophenolate mofetil
   Bristol-Myers Squibb
      2007   Phase 2/Phase 3   NCT00430677   Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2008   Phase 2;Phase 3   EUCTR2005-004575-37-GB   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-FR   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-BE   Belgium;France;United Kingdom
   Chinese SLE Treatment And Research Group
      2023   Phase 4   NCT05916781   China
   Fen Li
      2022   Phase 4   NCT05666336   China
   Genentech, Inc.
      2008   Phase 3   NCT00626197   United States
      2007   Phase 3   NCT00539838   United States
   Guy's & St Thomas' NHS Foundation Trust
      2005   Phase 4   EUCTR2005-001688-74-GB   United Kingdom
   Guy's and St Thomas' NHS Foundation Trust
      2006   Phase 4   NCT01101802   United Kingdom
   Imperial College London
      2015   Phase 3   NCT01773616   United Kingdom
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 2   NCT05306873   United States
      2013   Phase 2   NCT01946880   United States
      2005   Phase 2   NCT00230035   United States
   Oklahoma Medical Research Foundation
      2006   Phase 1/Phase 2   NCT00594932   United States
   Peking Union Medical College Hospital
      2023   Phase 4   ChiCTR2300072897   China
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 1/Phase 2   NCT02080195   United States
   Teva Branded Pharmaceutical Products R&D, Inc.
      2010   Phase 2   NCT01085097   Canada;France;Russian Federation;United Kingdom;United States
   The University of Hong Kong
      2015   -   JPRN-UMIN000025328   Japan,Asia(except Japan)
   University of Sao Paulo General Hospital
      2018   -   NCT03492255   Brazil
Mycophenolate mofetil 500MG
   Assiut University
      2021   Phase 3   NCT05057481   Egypt
   Ruijin Hospital
      2018   Phase 4   ChiCTR1800017540   China
Mycophenolate motetil
   Guy's & St Thomas' NHS Foundation Trust
      2005   Phase 4   EUCTR2005-001688-74-GB   United Kingdom
Mycophenolic acid
   Manuel Praga Terente
      2010   -   EUCTR2009-017273-38-ES   Spain
   NOVARTIS FARMA
      2006   -   EUCTR2006-002107-13-IT   France;Germany;Greece;Hungary;Italy;Spain;United Kingdom
Myfortic
   Cambridge University Hospitals NHS Foundation Trust
      2005   Phase 2   EUCTR2005-002207-16-GB   United Kingdom
   Novartis Pharma Services AG
      2006   Phase 2   EUCTR2005-003070-19-HU   Hungary
Myfortic*50CPR RIV 360MG
   NOVARTIS FARMA
      2006   -   EUCTR2006-002107-13-IT   France;Germany;Greece;Hungary;Italy;Spain;United Kingdom
N-(5-{4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl}[1,2,4]triazolo[1,5-A]pyridin-2-YL)cyclopropanecarboxamide
   GlaxoSmithKline Research and Development Limited
      2013   -   EUCTR2012-001645-41-SE   Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand
      2013   -   EUCTR2012-001645-41-PL   Argentina;Brazil;Chile;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Thailand
      2013   -   EUCTR2012-001645-41-DE   Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand
      2013   -   EUCTR2012-001645-41-CZ   Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand
      2012   -   EUCTR2012-001645-41-HU   Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand
      2012   -   EUCTR2012-001645-41-GR   Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand
      2012   Phase 2   EUCTR2012-001645-41-EE   Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Korea, Republic of;Peru;Poland;South Africa;Spain;Sweden
   GlaxoSmithKline, S.A.
      2012   -   EUCTR2012-001645-41-ES   Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand
N-acetylcysteine
   State University of New York - Upstate Medical University
      2022   Phase 2   NCT00775476   United States
Nelfinavir
   Northwell Health
      2014   Phase 2   NCT02066311   United States
NI-0501
   Swedish Orphan Biovitrum AG (Sobi AG)
      2022   Phase 2;Phase 3   EUCTR2021-001577-24-CZ   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-001577-24-SE   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States
Nicotinamide
   Second Xiangya Hospital of Central South University
      2017   Phase 2   NCT03260166   China
Nicotinamide riboside
   National Heart, Lung, and Blood Institute (NHLBI)
      2024   Phase 1/Phase 2   NCT06032923   United States
Nipocalimab
   Janssen Research & Development, LLC
      2021   Phase 2   NCT04882878   Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States
   Janssen-Cilag International NV
      2021   Phase 2   EUCTR2020-005569-14-PL   Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States
      2021   Phase 2   EUCTR2020-005569-14-HU   Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States
      2021   Phase 2   EUCTR2020-005569-14-ES   Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States
      2021   Phase 2   EUCTR2020-005569-14-BG   Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States
   Nishikawa Kazuko
      2022   Phase 2   JPRN-jRCT2041210058   Bulgaria;Colombia;Germany;Hungary;Japan;Poland;South Africa;Spain;Taiwan, Province Of China;Ukraine;United States OfAmerica
Nivolumab
   Alliance Foundation Trials, LLC.
      2019   Phase 1   NCT03656627   United States
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
NK 010 or NK042
   Guangdong Provincial People's Hospital
      2025   Phase 1   NCT06676631   China
NK cells
   Changhai Hospital
      2023   Early Phase 1   NCT06010472   China
NKX019
   Columbia University
      2024   Phase 1   NCT06518668   United States
NNC 0151-0000-0000
   Novo Nordisk A/S
      2009   Phase 1   NCT01018238   United States
      2008   Phase 1   NCT02151409   Netherlands
NNC0114-0006
   Novo Nordisk A/S
      2012   Phase 1   NCT01689025   Hungary;Poland;Serbia;United States
NON applicabile
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 2   EUCTR2021-001567-25-IT   Argentina;Chile;Germany;Greece;Hungary;Italy;Mexico;Russian Federation;Spain;Turkey;Ukraine;United States
Norethindrone
   Bristol-Myers Squibb
      2017   Phase 1   NCT03262727   United States
   National Center for Research Resources (NCRR)
      2000   -   NCT00006133   United States
Normal saline
   University of Leeds
      2017   Phase 2   NCT03054259   United Kingdom
NOX-E36
   NOXXON Pharma AG
      2009   Phase 1   NCT00976729   United Kingdom
OBE-CEL
   Autolus Limited
      2024   Phase 1   NCT06333483   Spain;United Kingdom
Obecabtagene autoleucel
   Autolus Limited
      2024   Phase 1   NCT06333483   Spain;United Kingdom
Obexelimab
   Zenas BioPharma (USA), LLC
      2024   Phase 2   NCT06559163   Belgium;Bulgaria;Canada;China;Germany;Greece;Italy;Japan;Mexico;Poland;Portugal;Puerto Rico;Romania;Spain;Taiwan;United States
Obinutuzumab
   Artiva Biotherapeutics, Inc.
      2024   Phase 1   NCT06265220   United States
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-005760-57-IT   Argentina;Australia;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2023   Phase 3   EUCTR2020-005760-57-CZ   Argentina;Australia;Brazil;Czech Republic;Czechia;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005760-57-PL   Argentina;Australia;Brazil;Czech Republic;Czechia;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005760-57-FR   Argentina;Australia;Brazil;Czech Republic;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
   Hoffmann-La Roche
      2021   Phase 3   NCT04963296   Argentina;Brazil;Czechia;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-005760-57-ES   Argentina;Australia;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
   Yoshiya Tanaka
      2023   Phase 3   JPRN-jRCT2071230031   -
Obinutuzumab administration
   Assistance Publique - Hôpitaux de Paris
      2021   Phase 3   NCT04702256   France
Ocrelizumab
   F. Hoffmann-La Roche Ltd
      2008   -   EUCTR2006-005357-29-SE   Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005357-29-PT   Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2006-005357-29-NL   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2006-005357-29-GB   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005357-29-DE   Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005357-29-BG   Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-SE   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-PT   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2006-005355-16-PL   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-NL   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-GB   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-DE   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005357-29-HU   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005357-29-FR   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005355-16-HU   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005355-16-FR   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      -   Phase 3   EUCTR2006-005357-29-PL   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
   Genentech, Inc.
      2008   Phase 3   NCT00626197   United States
      2007   Phase 3   NCT00539838   United States
OL-108
   Beijing GoBroad Hospital
      2025   Phase 1   NCT06980597   China
Olive OIL
   Universidad de Granada
      2021   -   NCT05261529   Spain
   University of Texas Southwestern Medical Center
      2012   Phase 2   NCT02021513   United States
Olumiant
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 3   EUCTR2017-005028-11-IT   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States
   Eli Lilly and Company
      2020   Phase 3   EUCTR2017-005028-11-NL   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2017-005028-11-HR   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2020   Phase 3   EUCTR2017-005028-11-GR   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-RO   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-PL   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-HU   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-GB   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Czech Republic;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-ES   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-DE   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-CZ   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005028-11-AT   Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005027-25-PL   Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States
      2019   Phase 3   EUCTR2017-005026-37-NL   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Czechia;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005026-37-HR   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005026-37-GR   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-005026-37-GB   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005027-25-ES   Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States
      2018   Phase 3   EUCTR2017-005026-37-HU   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005026-37-CZ   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005026-37-BE   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005026-37-AT   Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Czechia;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States
Olumiant - EU/1/16/1170/001-008
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2018   Phase 3   EUCTR2017-005027-25-IT   Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States
Olumiant - EU/1/16/1170/009-016
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2018   Phase 3   EUCTR2017-005027-25-IT   Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States
Omacor
   GreenPark Healthcare Trust
      2004   Phase 4   EUCTR2004-004404-21-GB   United Kingdom
Omega-3
   Michelle Petri M.D.,MPH
      2009   Phase 4   NCT00828178   United States
Oral prednisolone
   Imperial College London
      2015   Phase 3   NCT01773616   United Kingdom
   Zenyaku Kogyo Co., Ltd.
      2007   -   JPRN-UMIN000000639   Japan
Oral prednisone 5MG
   University of Pisa
      2019   -   NCT03804723   -
Orelabrutinib
   Beijing InnoCare Pharma Tech Co., Ltd.
      2023   Phase 2   NCT05688696   China
Orencia
   Bristol-Myers Squibb International Corporation
      2008   Phase 2;Phase 3   EUCTR2005-004575-37-GB   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-BE   Belgium;France;United Kingdom
Orencia 125 MG solution FOR injection IN PRE-filled syringe
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
Ortho-novum 777
   New York University School of Medicine
      1997   Phase 3   NCT00000420   United States
Oxygen
   Guangdong Provincial Hospital of Chinese Medicine
      2017   -   ChiCTR-IOR-17012802   China
Ozone
   Guangdong Provincial Hospital of Chinese Medicine
      2017   -   ChiCTR-IOR-17012802   China
P 140
   IMMUPHARMA SA
      2008   -   EUCTR2007-004892-21-BG   Bulgaria;Spain
P-CD19cd20-ALLO1 cells
   Genentech, Inc.
      2025   Phase 1   NCT06984341   -
Paquinimod
   Active Biotech AB
      2009   Phase 2   NCT00997100   Denmark;Sweden
   Active Biotech Research AB
      2009   -   EUCTR2009-011245-55-SE   Denmark;Sweden
      2009   -   EUCTR2009-011245-55-DK   Denmark;Sweden
PF-04236921
   Pfizer
      2011   Phase 2   NCT01405196   Argentina;Chile;Colombia;Germany;Hungary;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Poland;Puerto Rico;Romania;Taiwan;United States
   Pfizer Inc.235 East 42nd Street, New York, NY 10017
      2012   -   EUCTR2011-000420-15-HU   Argentina;Chile;Colombia;Germany;Hungary;India;Israel;Korea, Republic of;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Taiwan;United States
      2012   -   EUCTR2011-000420-15-DE   Argentina;Chile;Colombia;Germany;Hungary;India;Israel;Korea, Republic of;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Taiwan;United States
PF-06700841 15 MG
   Pfizer
      2019   Phase 2   NCT03845517   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
PF-06700841 25MG
   PFIZER INC
      2021   Phase 2   EUCTR2018-004175-12-IT   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
   Pfizer Inc.
      2019   Phase 2   EUCTR2018-004175-12-RO   Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-PT   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-PL   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-HU   Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-GB   Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-ES   Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-DE   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-BG   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-BE   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
PF-06700841 30 MG
   Pfizer
      2019   Phase 2   NCT03845517   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
PF-06700841 45 MG
   Pfizer
      2019   Phase 2   NCT03845517   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
PF-06700841 5MG
   Pfizer Inc.
      2019   Phase 2   EUCTR2018-004175-12-RO   Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-PT   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-PL   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-HU   Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-GB   Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-ES   Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-DE   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-BG   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-BE   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
PF-06700841-15
   PFIZER INC
      2021   Phase 2   EUCTR2018-004175-12-IT   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
   Pfizer Inc.
      2019   Phase 2   EUCTR2018-004175-12-RO   Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-PT   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-PL   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-HU   Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-GB   Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-ES   Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-DE   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-BG   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004175-12-BE   Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
PF-06835375
   Pfizer
      2017   Phase 1   NCT03334851   Puerto Rico;United States
Pharmacokinetic analysis
   Sun Yat-sen University
      2010   -   NCT01060410   China
Phosphate-buffered saline
   La Jolla Pharmaceutical Company
      2004   Phase 3   NCT00089804   Argentina;Australia;Belarus;Brazil;Bulgaria;Czech Republic;Former Serbia and Montenegro;Georgia;Germany;Hong Kong;Hungary;India;Indonesia;Italy;Korea, Republic of;Lebanon;Malaysia;Mexico;Philippines;Poland;Portugal;Puerto Rico;Romania;Serbia;Slovakia;Spain;Sri Lanka;Taiwan;Thailand;Ukraine;United States
Physical examination
   LiveKidney.Bio
      2025   Phase 1   NCT06737380   United States
Physical exercise program
   Universidad de Granada
      2021   -   NCT05261529   Spain
Pioglitazone
   National Heart Institute, Mexico
      2007   Phase 4   NCT01322308   -
PIT565
   Novartis Pharmaceuticals
      2024   Phase 1   NCT06335979   Bulgaria;Germany;Netherlands;Spain;Switzerland
Pitavastatin
   Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
      2014   Phase 2   JPRN-UMIN000008230   Japan
   Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College.
      2024   -   ChiCTR2400084812   China
   Nakashima Yasuharu
      2014   Phase 2   JPRN-jRCTs071180052   -
Plaquenil
   Christine Bengtsson
      2015   Phase 2   EUCTR2014-005418-45-SE   Sweden
Plasmapheresis
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00230035   United States
Pneumovax
   University of Alabama at Birmingham
      2007   -   NCT00611611   United States
Polymorphism analysis
   Sun Yat-sen University
      2010   -   NCT01060410   China
Pooled mesenchymal stem cell
   Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
      2019   Phase 1/Phase 2   NCT04184258   Belarus
Positron emission tomography
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States
Prasterone
   Genelabs Technologies
      2003   Phase 3   NCT00082511   Mexico;United States
      2002   Phase 3   NCT00053560   Mexico;United States
Pravastatin
   Brigham and Women's Hospital
      2003   Phase 2   NCT00054938   United States
PRE-filled syringe
   Ablynx N.V.
      2015   Phase 2   EUCTR2015-000372-95-PT   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2015   Phase 2   EUCTR2015-000372-95-HU   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2015   Phase 2   EUCTR2015-000372-95-ES   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2015   Phase 2   EUCTR2015-000372-95-DE   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2015   Phase 2   EUCTR2015-000372-95-CZ   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
   AstraZeneca
      2022   Phase 3   EUCTR2020-004529-22-DE   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Thailand;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004529-22-HU   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Thailand;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004529-22-BG   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Thailand;Ukraine;United Kingdom;United States
   Dr Josep Ordi Ros
      2012   Phase 2   EUCTR2011-005392-16-ES   Spain
   Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
      2012   Phase 3   EUCTR2011-003814-18-SE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003814-18-DK   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   -   EUCTR2011-003814-18-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
   Human Genome Sciences, Inc.
      2012   -   EUCTR2011-003814-18-ES   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   -   EUCTR2011-003814-18-CZ   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
   Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
      2012   -   EUCTR2011-003814-18-HU   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   -   EUCTR2011-003814-18-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003814-18-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   Phase 3   EUCTR2011-003814-18-BE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
   Human Genome Sciences, Inc. (a wholy owned subsidiary of GlaxoSmithKline PLC)
      2012   Phase 3   EUCTR2011-003814-18-GB   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
   Human Genome Sciences, a wholly owned subsidiary of GlaxoSmithKline, Plc
      2012   Phase 3   EUCTR2011-003814-18-PT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
      2012   -   EUCTR2011-003814-18-PL   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
   Janssen-Cilag International N.V.
      2015   Phase 2   EUCTR2014-005000-19-PL   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-005000-19-HU   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-005000-19-ES   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-005000-19-DE   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
   Janssen-Cilag International NV
      2019   Phase 3   EUCTR2017-001489-53-PT   Argentina;Bulgaria;Canada;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-PL   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-LT   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-HU   Argentina;Australia;Bulgaria;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-ES   Argentina;Australia;Bulgaria;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-DE   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-BG   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
   Merck KGaA
      2014   Phase 2   EUCTR2013-002773-21-IT   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002773-21-GB   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002773-21-ES   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002773-21-DE   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002773-21-CZ   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002758-62-IT   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002758-62-GB   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002758-62-ES   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002758-62-DE   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002758-62-CZ   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2014   Phase 2   EUCTR2013-002758-62-BG   Argentina;Brazil;Bulgaria;Chile;Czech Republic;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
   NOVARTIS PHARMA AG
      2023   Phase 3   EUCTR2022-002690-29-IT   Argentina;Australia;Chile;Colombia;France;Germany;India;Italy;Korea, Republic of;Mexico;Romania;Taiwan;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2022   Phase 3   EUCTR2022-002691-36-ES   Brazil;Bulgaria;Canada;China;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Turkey;United States
   Novartis Pharma AG
      2023   Phase 3   EUCTR2022-002691-36-SK   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Turkey;United States
      2023   Phase 3   EUCTR2022-002691-36-PT   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Türkiye;United States
      2023   Phase 3   EUCTR2022-002691-36-PL   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Türkiye;United States
      2023   Phase 3   EUCTR2022-002691-36-HU   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Turkey;United States
      2023   Phase 3   EUCTR2022-002691-36-CZ   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Turkey;United States
      2023   Phase 3   EUCTR2022-002691-36-BG   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Türkiye;United States
      2023   Phase 3   EUCTR2022-002690-29-RO   Argentina;Australia;Chile;Colombia;France;Germany;India;Italy;Korea, Republic of;Mexico;Romania;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002690-29-FR   Argentina;Australia;Chile;Colombia;France;Germany;India;Italy;Korea, Republic of;Mexico;Romania;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002690-29-DE   Argentina;Australia;Chile;France;Germany;India;Italy;Korea, Republic of;Mexico;Romania;South Africa;Spain;Taiwan;United Kingdom;United States
   University of Utah
      2021   Phase 2   EUCTR2020-001177-78-FR   France;United States
Prednisolone
   Atsumi Tatsuya
      2020   Phase 4   JPRN-jRCTs011190011   -
   Bristol-Myers Squibb
      2007   Phase 2/Phase 3   NCT00430677   Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States
   Guang'anmen Hospital, China Academy of Chinese Medical Sciences
      2023   Phase 1   ChiCTR2300073848   China
   Japanese Study Group of Renal Disease in Children(JSRDC)
      2006   -   JPRN-C000000159   Japan
      1995   -   JPRN-C000000378   Japan
   University Hospital Gent
      -   Phase 3   EUCTR2005-003957-28-BE   Belgium;Denmark;Italy
Prednisolone/prednisone
   Teva Branded Pharmaceutical Products R&D, Inc.
      2010   Phase 2   NCT01085097   Canada;France;Russian Federation;United Kingdom;United States
Prednisona
   Manuel Praga Terente
      2010   -   EUCTR2009-017273-38-ES   Spain
Prednisone
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 4   EUCTR2017-002050-36-FR   France
   Ampel BioSolutions, LLC
      2017   Phase 4   NCT03098823   United States
   Bristol-Myers Squibb
      2007   Phase 2/Phase 3   NCT00430677   Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States
      2005   Phase 2   NCT00119678   Australia;Austria;Belgium;Brazil;Canada;France;Germany;Italy;Korea, Republic of;Mexico;Puerto Rico;South Africa;Sweden;Taiwan;United Kingdom;United States
   DualityBio Inc.
      2024   Phase 1   NCT06625671   Australia
   Fairview University Medical Center
      2000   -   NCT00006055   United States
   Fen Li
      2022   Phase 4   NCT05666336   China
   Genentech, Inc.
      2007   Phase 3   NCT00539838   United States
      2005   Phase 2/Phase 3   NCT00137969   Canada;United States
   Guang'anmen Hospital, China Academy of Chinese Medical Sciences
      2023   Phase 1   ChiCTR2300073848   China
   ISTITUTO GIANNINA GASLINI
      2006   Phase 3   EUCTR2005-003957-28-IT   Belgium;Denmark;Italy
   Manuel Praga Terente
      2010   -   EUCTR2009-017273-38-ES   Spain
   NOVARTIS FARMA
      2006   -   EUCTR2006-002107-13-IT   France;Germany;Greece;Hungary;Italy;Spain;United Kingdom
   NOVARTIS PHARMA AG
      2023   Phase 3   EUCTR2022-002690-29-IT   Argentina;Australia;Chile;Colombia;France;Germany;India;Italy;Korea, Republic of;Mexico;Romania;Taiwan;United Kingdom;United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2013   Phase 2   NCT01946880   United States
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1986   Phase 2   NCT00001212   United States
   New York University School of Medicine
      1997   Phase 2   NCT00000421   United States
   Peking University First Hospital
      2021   -   ChiCTR2100048635   China
   Ruijin Hospital
      2018   Phase 4   ChiCTR1800017540   China
   The First Affiliated Hospital of Anhui University of Chinese Medicine 
      2024   -   ChiCTR2500097024   China
   University of Sao Paulo General Hospital
      2018   -   NCT03492255   Brazil
   Zhejinag University of Chinese Medicine
      2008   Phase 3 study   ChiCTR-TRC-12001935   China
Prednisone acetate
   Nanjing University of Chinese Medicine Affiliated Hospital
      2019   Phase 1   ChiCTR1900022934   China
      2019   Phase 1 study   ChiCTR1800020286   China
   The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
      2017   -   ChiCTR-INR-17011495   China
Prednisone discontinuation
   Groupe Hospitalier Pitie-Salpetriere
      2014   Phase 3   NCT02558517   France
Pregnancy test
   LiveKidney.Bio
      2025   Phase 1   NCT06737380   United States
Premarin and provera
   New York University School of Medicine
      1996   Phase 3   NCT00000419   United States
Progressive resisted exercise training
   Cairo University
      2022   -   NCT05392790   Egypt
Proleukin
   Charité - Universitätsmedizin Berlin
      2014   Phase 1;Phase 2   EUCTR2013-001599-40-DE   Germany
   Onur Boyman, MD
      2018   Phase 2   NCT03312335   Switzerland
PRV-3279
   Provention Bio, a Sanofi Company
      2022   Phase 2   NCT05087628   China;Hong Kong;Puerto Rico;United States
Questionnaires
   University Hospital, Bordeaux
      2021   -   NCT04276701   France;Germany;Spain
Quinipril
   University Health Network, Toronto
      2002   Phase 4   NCT00188188   Canada
R-salbutamol sulphate
   Astion Pharma A/S
      2007   -   EUCTR2007-004635-29-SE   Denmark;Spain;Sweden
      2007   Phase 3   EUCTR2007-004635-29-DK   Denmark;Spain;Sweden
R932333
   Rigel Pharmaceuticals
      2012   Phase 2   NCT01597050   Canada;United States
Rabbit ANTI-thymocyte globulin
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00230035   United States
Rabbit antithymocyte globulin
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 1/Phase 2   NCT02080195   United States
Ramipril
   Brigham and Women's Hospital
      2003   Phase 2   NCT00054938   United States
   Federal University of São Paulo
      2011   Phase 2/Phase 3   NCT03979976   Brazil
Rankl/OPG ratio
   Centre Hospitalier Universitaire, Amiens
      2011   -   NCT02799173   France
Rapamycin
   State University of New York - Upstate Medical University
      2008   Phase 2   NCT00779194   United States
   the Second Hospital of Shanxi Medical University
      2016   -   ChiCTR-IPR-16009451   China
Rapcabtagene autoleucel regimen 1
   Novartis Pharmaceuticals
      2024   Phase 2   NCT06581198   France;Germany;Italy;Japan;Netherlands;Singapore;Spain;United States
Rapcabtagene autoleucel regimen 2
   Novartis Pharmaceuticals
      2024   Phase 2   NCT06581198   France;Germany;Italy;Japan;Netherlands;Singapore;Spain;United States
Raptiva
   Universitätskrankenhaus Schleswig-Holstein
      2009   -   EUCTR2008-003833-25-DE   Germany
Rayos
   Ampel BioSolutions, LLC
      2017   Phase 4   NCT03098823   United States
RC18 160 MG plus standard therapy
   RemeGen
      2015   Phase 2   NCT02885610   China
   RemeGen Co., Ltd.
      2019   Phase 3   NCT04082416   China
RC18 240 MG plus standard therapy
   RemeGen
      2015   Phase 2   NCT02885610   China
RC18 80 MG plus standard therapy
   RemeGen
      2015   Phase 2   NCT02885610   China
RD06-04 cart cell injection
   Nanjing Bioheng Biotech Co., Ltd.
      2024   Early Phase 1   NCT06549296   China
RD06-04 cells injection
   Wuhan Union Hospital, China
      2024   -   NCT06310811   China
Recombinant factor FC fusion protein
   AMGEN INC.
      2021   Phase 2   EUCTR2020-003509-72-IT   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
   Amgen Inc
      2018   Phase 1;Phase 2   EUCTR2017-002564-40-DE   France;Germany;Poland;United States
   Amgen Inc.
      2021   Phase 2   EUCTR2020-003509-72-PL   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-GR   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-FR   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-ES   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-BG   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States
      2021   Phase 2   EUCTR2020-003509-72-AT   Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United States
Recombinant zoster vaccine
   RenJi Hospital
      2021   -   NCT04516408   China
Reduced intensity allogeneic transplant
   New York Medical College
      2007   Phase 1   NCT00684255   United States
Relma-CEL
   Shanghai Ming Ju Biotechnology Co., Ltd.
      2024   Phase 1   NCT06297408   -
      2023   Phase 1   NCT05765006   China
Remicade
   Department of Rheumatology, Internal Medicine III, Medical University of Vienna
      2006   -   EUCTR2005-004067-30-NL   Austria;Germany;Netherlands
      2006   -   EUCTR2005-004067-30-DE   Austria;Germany;Netherlands
      2006   -   EUCTR2005-004067-30-AT   Austria;Germany;Netherlands
Rest OF ANA profile
   Sohag University
      2024   -   NCT06294483   Egypt
Rhumab 2h7
   F. Hoffmann-La Roche Ltd
      2008   -   EUCTR2006-005357-29-SE   Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005357-29-PT   Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2006-005357-29-NL   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2006-005357-29-GB   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005357-29-DE   Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005357-29-BG   Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-SE   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-PT   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2006-005355-16-PL   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-NL   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-GB   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-DE   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005357-29-HU   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005357-29-FR   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005355-16-HU   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005355-16-FR   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      -   Phase 3   EUCTR2006-005357-29-PL   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Rhumab ifnalpha
   Genentech, Inc.
      2007   Phase 1   NCT00541749   United States
Rigerimod
   Cephalon, Inc.
      2010   -   EUCTR2010-019293-32-HU   Czech Republic;Hungary;Portugal;Spain
      2010   Phase 3   EUCTR2010-019293-32-ES   Belgium;Czech Republic;Germany;Hungary;Portugal;Spain
      2010   Phase 2   EUCTR2010-018383-16-FR   Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain
      2010   Phase 2   EUCTR2010-018383-16-ES   Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain
Rimiducid
   Genentech, Inc.
      2025   Phase 1   NCT06984341   -
Riquent
   AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
      2009   -   EUCTR2008-004852-62-IT   Italy
   La Jolla Pharmaceutical Company
      2008   -   EUCTR2006-000674-73-BG   Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain
Rituximab
   Artiva Biotherapeutics, Inc.
      2024   Phase 1   NCT06265220   United States
   Assiut University
      2021   Phase 3   NCT05057481   Egypt
   Cambridge University Hospitals NHS Foundation Trust
      2002   Phase 2   NCT00293072   United Kingdom
   Chinese SLE Treatment And Research Group
      2023   Phase 4   NCT05828147   China
   Chinese University of Hong Kong
      2006   Phase 2   NCT00556192   China
   European Society for Blood and Marrow Transplantation
      2009   Phase 2/Phase 3   NCT05063513   France
   Genentech, Inc.
      2006   Phase 3   NCT00381810   United States
      2005   Phase 2/Phase 3   NCT00137969   Canada;United States
   GlaxoSmithKline
      2018   Phase 3   NCT03312907   Argentina;Brazil;Canada;France;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States
   GlaxoSmithKline Research & Development Ltd
      2018   Phase 3   EUCTR2016-003050-32-NL   Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States
      2018   Phase 3   EUCTR2016-003050-32-DE   Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States
   GlaxoSmithKline, S.A.
      2017   Phase 3   EUCTR2016-003050-32-ES   Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;South Africa;Spain;United States
   Guangdong Provincial People's Hospital
      2025   Phase 1   NCT06676631   China
   IRIS Research and Development, LLC
      2024   Phase 1   NCT06581562   United States
   Imperial College London
      2015   Phase 3   NCT01773616   United Kingdom
   Leiden University Medical Center
      2014   Phase 2   EUCTR2014-000488-42-NL   Netherlands
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00076752   United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00230035   United States
      2001   Phase 1/Phase 2   NCT00036491   United States
   The First Hospital of China Medical University
      2023   Phase 4   ChiCTR2300070865   China
   University of Leeds
      2017   Phase 2   NCT03054259   United Kingdom
   Zenyaku Kogyo Co., Ltd.
      2007   -   JPRN-UMIN000000763   Japan
Rivaroxaban
   University College London
      2019   Phase 2;Phase 3   EUCTR2018-001735-49-GB   United Kingdom
      2012   Phase 2   EUCTR2012-002345-38-GB   United Kingdom
   University College, London
      2021   Phase 2   NCT03684564   United Kingdom
Rixathon
   A.S.L. TO 2
      2022   Phase 3   EUCTR2021-006544-26-IT   Italy
RO 106-1443
   Guy's & St Thomas' NHS Foundation Trust
      2005   Phase 4   EUCTR2005-001688-74-GB   United Kingdom
RO 496-4913
   F. Hoffmann-La Roche Ltd
      2008   -   EUCTR2006-005357-29-SE   Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005357-29-PT   Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2006-005357-29-NL   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2006-005357-29-GB   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005357-29-DE   Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005357-29-BG   Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-SE   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-PT   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2006-005355-16-PL   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-NL   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-GB   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2008   -   EUCTR2006-005355-16-DE   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005357-29-HU   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005357-29-FR   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-005355-16-HU   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-005355-16-FR   France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      -   Phase 3   EUCTR2006-005357-29-PL   Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
RO 5072759
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-005760-57-FR   Argentina;Australia;Brazil;Czech Republic;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States
RO7010939/F13
   Genentech, Inc.
      2018   Phase 2   EUCTR2017-001764-37-PT   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001764-37-GB   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001764-37-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-001039-11-PT   Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-001039-11-ES   Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-001039-11-DE   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-001039-11-BG   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
      2016   Phase 2   EUCTR2016-001039-11-GB   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
   Roche Farma, S.A por delegación de Genentech, Inc.
      2017   Phase 2   EUCTR2017-001764-37-ES   Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States
RO7507062
   Hoffmann-La Roche
      2023   Phase 1   NCT05835986   Colombia;France;Germany;Malaysia;Mexico;Netherlands;Peru;Poland;South Africa;Spain;Taiwan;Thailand;United Kingdom
Rontalizumab
   Chugai Pharmaceutical Co., Ltd.
      2012   Phase 1   JPRN-jRCT2080221821   -
   Genentech, Inc.
      2009   Phase 2   NCT00962832   Argentina;Colombia;Mexico;Poland;Russian Federation;United Kingdom;United States
Rosuvastatin
   GlaxoSmithKline
      2013   Phase 1   NCT01953835   United States
   Imperial College London
      2010   Phase 2   NCT01170585   United Kingdom
   Ramathibodi Hospital
      2008   Phase 4   NCT00866229   Thailand
   Tuen Mun Hospital
      2006   Phase 4   NCT00371501   Hong Kong
Rosuvastatin calcium
   Imperial College
      2010   Phase 4   EUCTR2006-006214-16-GB   United Kingdom
Royal jelly
   Faculty of medicine, University of Assiut, Assiut 71516, Egypt.
      2015   -   JPRN-UMIN000020859   Africa
Rozibafusp alfa
   Amgen
      2020   Phase 2   NCT04058028   Argentina;Australia;Bulgaria;Canada;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Spain;United States
   Amgen K.K.
      2020   Phase 2   JPRN-jRCT2080225306   Argentina;Australia;Bulgaria;Canada;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Korea;Mexico;Poland;Portugal;Russian Federation;Spain;United States
RSLV-132
   Resolve Therapeutics
      2016   Phase 2   NCT02660944   United States
      2014   Phase 1   NCT02194400   United States
Saccharum lactis
   Universitas Padjadjaran
      2022   Phase 2/Phase 3   NCT06618573   Indonesia
Saliva sample
   University Hospital, Brest
      2023   -   NCT05747651   France
      2022   Phase 3   NCT05458622   France
Saphnelo
   AstraZeneca
      2022   Phase 3   EUCTR2020-004529-22-DE   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Thailand;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004529-22-HU   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Thailand;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004529-22-BG   Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Thailand;Ukraine;United Kingdom;United States
SAR113244
   Sanofi
      2016   Phase 1   NCT02331810   -
      2014   Phase 1   NCT02321709   Germany
SAR441344
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 2   EUCTR2021-001567-25-IT   Argentina;Chile;Germany;Greece;Hungary;Italy;Mexico;Russian Federation;Spain;Turkey;Ukraine;United States
   Sanofi-Aventis Recherche et Développement
      2022   Phase 2   EUCTR2021-001567-25-HU   Argentina;Brazil;Chile;Germany;Greece;Hungary;Italy;Mauritius;Mexico;Russian Federation;Spain;Turkey;Ukraine;United States
      2021   Phase 2   EUCTR2021-001567-25-ES   Argentina;Chile;Germany;Greece;Italy;Mexico;Russian Federation;Spain;Turkey;Ukraine;United States
      2021   Phase 2   EUCTR2021-001567-25-DE   Argentina;Chile;Germany;Greece;Italy;Mexico;Russian Federation;Spain;Turkey;Ukraine;United States
SAR441344 IV
   Sanofi
      2021   Phase 2   NCT05039840   Argentina;Brazil;Chile;Georgia;Greece;Hungary;Italy;Mauritius;Mexico;Puerto Rico;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United States
SAR441344 SC
   Sanofi
      2021   Phase 2   NCT05039840   Argentina;Brazil;Chile;Georgia;Greece;Hungary;Italy;Mauritius;Mexico;Puerto Rico;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United States
SBI-087
   Pfizer
      2009   Phase 1   NCT00714116   Canada;United States
SC belimumab 200 MG
   GlaxoSmithKline
      2017   -   NCT03125486   United States
SC291
   Sana Biotechnology
      2024   Phase 1   NCT06294236   United States
SCRI-CAR19v3
   Seattle Children's Hospital
      2024   Phase 1   NCT06465147   United States
SCTB35 injection
   Sinocelltech Ltd.
      2025   Phase 1/Phase 2   NCT06841042   China
Seluang fish OIL (rasbora argyrotaenia) and synbiotic
   Universitas Sriwijaya
      2024   -   NCT06659068   Indonesia
Serum creatinine and ALB/create ratio
   Sohag University
      2024   -   NCT06294483   Egypt
SF-36 questionnaire
   LiveKidney.Bio
      2025   Phase 1   NCT06737380   United States
SG301 SC injection
   Hangzhou Sumgen Biotech Co., Ltd.
      2023   Phase 1   NCT06144710   China
Shingrix
   Seoul National University Hospital
      2023   Phase 3   NCT06001606   Korea, Republic of
SHR-2173
   Guangdong Hengrui Pharmaceutical Co., Ltd
      2024   Phase 1   NCT06955598   China
Sifalimumab
   ASTRAZENECA
      2011   -   EUCTR2010-024069-30-IT   Argentina;Brazil;Bulgaria;Canada;Chile;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;South Africa;Spain;Thailand;United Kingdom;United States
   AstraZeneca AB
      2012   -   EUCTR2010-024069-30-BG   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
      2011   Phase 2   EUCTR2010-024069-30-NL   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
      2011   Phase 2   EUCTR2010-024069-30-GB   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
      2011   -   EUCTR2010-024069-30-ES   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
      2011   -   EUCTR2010-024069-30-DE   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
      -   -   EUCTR2010-024069-30-HU   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
   MedImmune LLC
      2010   Phase 2   NCT00979654   Brazil;Canada;Chile;United States
Sifalimumab 1,200 MG
   MedImmune LLC
      2011   Phase 2   NCT01283139   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Jamaica;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
Sifalimumab 200 MG
   MedImmune LLC
      2011   Phase 2   NCT01283139   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Jamaica;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
Sifalimumab 600 MG
   MedImmune LLC
      2011   Phase 2   NCT01283139   Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Jamaica;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States
Simvastatin
   GlaxoSmithKline
      2013   Phase 1   NCT01953835   United States
   Merck Sharp & Dohme Corp.
      2007   Phase 4   NCT00739050   -
   Ramathibodi Hospital
      2008   Phase 4   NCT00866229   Thailand
Single dose OF UC-mscs
   LiveKidney.Bio
      2025   Phase 1   NCT06737380   United States
Sirolimus
   Chinese SLE Treatment And Research Group
      2021   Phase 2   NCT04582136   China
   State University of New York - Upstate Medical University
      2025   Phase 2   NCT04736953   -
SLE activity evaluation
   LiveKidney.Bio
      2025   Phase 1   NCT06737380   United States
SLE biomarker profiling
   LiveKidney.Bio
      2025   Phase 1   NCT06737380   United States
SLE treatment
   GlaxoSmithKline
      2013   -   NCT01729455   Argentina;Austria;Belgium;Canada;France;Germany;Israel;Italy;Portugal;Slovakia;Spain;Sweden;United States
Sledai scores
   Sohag University
      2024   -   NCT06294483   Egypt
SM101
   SuppreMol GmbH
      2012   -   EUCTR2010-023396-25-PL   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2012   -   EUCTR2010-023396-25-NL   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-023396-25-GB   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   -   EUCTR2010-023396-25-ES   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   -   EUCTR2010-023396-25-DE   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   -   EUCTR2010-023396-25-CZ   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-023396-25-BE   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
SM934
   RenJi Hospital
      2019   Phase 2   NCT03951259   China
Smartphone application
   Northwestern University
      2014   -   NCT02281513   United States
SOLU-medrol 1MG/KG
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2020   Early Phase 1   NCT04233164   United States
SOLU-medrol 250 MG
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2020   Early Phase 1   NCT04233164   United States
Soluble FC receptor
   SuppreMol GmbH
      2012   -   EUCTR2010-023396-25-PL   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2012   -   EUCTR2010-023396-25-NL   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-023396-25-GB   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   -   EUCTR2010-023396-25-ES   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   -   EUCTR2010-023396-25-DE   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   -   EUCTR2010-023396-25-CZ   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-023396-25-BE   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
Soluble FC-gamma receptor IIB
   SuppreMol GmbH
      2012   -   EUCTR2010-023396-25-PL   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2012   -   EUCTR2010-023396-25-NL   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-023396-25-GB   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   -   EUCTR2010-023396-25-ES   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   -   EUCTR2010-023396-25-DE   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   -   EUCTR2010-023396-25-CZ   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-023396-25-BE   Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
SQ fludarabine
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      1998   Phase 1   NCT00001676   United States
ST 36
   Guangdong Provincial Hospital of Chinese Medicine
      2017   -   ChiCTR-IOR-17012802   China
Standard dose OF HCQ
   University of Sao Paulo General Hospital
      2017   Phase 4   NCT03122431   Brazil
Standard dose OF rituximab
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   Phase 4   NCT04127747   China
Standard therapy
   Affiliated Hospital of Guilin Medical College
      2021   Phase 4   ChiCTR2100052342   China
   GlaxoSmithKline
      2021   Phase 4   NCT04908865   China
      2018   Phase 3   NCT03312907   Argentina;Brazil;Canada;France;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States
   Human Genome Sciences Inc., a GSK Company
      2011   Phase 3   NCT01484496   Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Malaysia;Mexico;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States
   RemeGen Co., Ltd.
      2022   Phase 1   NCT05247203   China
   The First Hospital of China Medical University
      2022   Phase 4   ChiCTR2200062250   China
Standard treatment according TO THE clinical protocols
   Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
      2019   Phase 1/Phase 2   NCT04184258   Belarus
Standard-OF-care treatment
   Janssen Research & Development, LLC
      2021   Phase 2   NCT04882878   Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States
Stelara
   Janssen-Cilag International N.V.
      2015   Phase 2   EUCTR2014-005000-19-PL   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-005000-19-HU   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-005000-19-ES   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-005000-19-DE   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
   Janssen-Cilag International NV
      2019   Phase 3   EUCTR2017-001489-53-PT   Argentina;Bulgaria;Canada;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-PL   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-LT   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-HU   Argentina;Australia;Bulgaria;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-ES   Argentina;Australia;Bulgaria;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-DE   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-BG   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
Steroid drug
   Mallinckrodt
      2013   Phase 4   NCT01753401   United States
Steroid taper
   GlaxoSmithKline
      2018   Phase 3   NCT03312907   Argentina;Brazil;Canada;France;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States
STK-009
   Synthekine
      2025   Phase 1   NCT06544330   United States
Stood sample
   University Hospital, Brest
      2022   Phase 3   NCT05458622   France
Stool sample
   University Hospital, Brest
      2023   -   NCT05747651   France
Subcuvia
   Department of Rheumatology,University hospital,Lund
      2007   -   EUCTR2006-004892-36-SE   Sweden
Sugar pill
   Guy's and St Thomas' NHS Foundation Trust
      2006   Phase 4   NCT01101802   United Kingdom
Sulfasalazine tablets
   Qiong Fu
      2024   Phase 2   NCT06360068   -
Sulfate
   Guang'anmen Hospital, China Academy of Chinese Medical Sciences
      2023   Phase 1   ChiCTR2300073848   China
   The First Affiliated Hospital of Anhui University of Chinese Medicine 
      2024   -   ChiCTR2500097024   China
   The Third Affiliated Hospital, Southern Medical University
      2018   -   ChiCTR1800019308   China
Switch TO myfortic
   Erasmus Medical Center
      2007   Phase 3   NCT00504244   Netherlands
Syncar-001
   Synthekine
      2025   Phase 1   NCT06544330   United States
SYS6020
   CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
      2024   Phase 1   NCT06694298   -
T cell injection targeting CD19 chimeric antigen receptor
   PersonGen BioTherapeutics (Suzhou) Co., Ltd.
      2024   Early Phase 1   NCT06417398   -
      2024   -   NCT06361745   China
T cells transduced with chimeric antigen receptor ANTI-CD19
   Miltenyi Biomedicine GmbH
      2023   Phase 1;Phase 2   EUCTR2022-003137-19-DE   Germany
TAB08
   Theramab LLC
      2016   Phase 2   NCT02711813   Russian Federation
Tabalumab AUTO-injector
   Eli Lilly and Company
      2014   Phase 3   NCT02041091   Korea, Republic of;Mexico;Puerto Rico;United States
Tabalumab prefilled syringe
   Eli Lilly and Company
      2014   Phase 3   NCT02041091   Korea, Republic of;Mexico;Puerto Rico;United States
TACI-FC5
   Merck Serono International
      2008   -   EUCTR2007-003698-13-BG   Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom
   Merck Serono International SA, An affiliate of Merck KGaA, Darmstadt, Germany
      2008   Phase 2;Phase 3   EUCTR2007-003698-13-FR   Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom
      2008   Phase 2;Phase 3   EUCTR2007-003698-13-ES   Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom
   Merck Serono S.A. Geneva. An affiliate of Merck KGaA, Darmstadt, Germany
      2008   -   EUCTR2007-003698-13-NL   Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States
      2008   -   EUCTR2007-003698-13-LV   Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-003698-13-LT   Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States
      2008   -   EUCTR2007-003698-13-GR   Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom
      2008   Phase 2;Phase 3   EUCTR2007-003698-13-GB   Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States
      2008   -   EUCTR2007-003698-13-CZ   Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Spain;Taiwan;United Kingdom;United States
      -   -   EUCTR2007-003698-13-DE   Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States
   Merck Serono SA - Geneva
      2008   -   EUCTR2007-003698-13-AT   Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom
Tacrolimus
   Chinese SLE Treatment And Research Group
      2023   Phase 4   NCT05916781   China
   Chinese University of Hong Kong
      2004   Phase 4   NCT00125307   China;Hong Kong
   Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
      2010   -   JPRN-UMIN000004182   Japan
   Fen Li
      2022   Phase 4   NCT05666336   China
   Peking Union Medical College Hospital
      2023   Phase 4   ChiCTR2300072897   China
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 1/Phase 2   NCT02080195   United States
   The University of Hong Kong
      2015   -   JPRN-UMIN000025328   Japan,Asia(except Japan)
TAK-079
   Millennium Pharmaceuticals, Inc.
      2018   Phase 1   NCT03724916   United States
Taking peripheral blood samples
   Assiut University
      2019   -   NCT03984227   -
Telitacicept
   Department of Dermatology, Second Affiliated Hospital of Xi 'an Jiaotong University
      2024   Phase 2   ChiCTR2400086459   China
   Fen Li
      2022   Phase 4   NCT05666336   China
   Guanmin Gao
      2023   Phase 2   NCT05929248   -
   Liu Tian
      2023   Phase 3   NCT05339217   China
   Peking Union Medical College Hospital
      2022   Phase 4   NCT05899907   China
   RemeGen Co., Ltd.
      2024   Phase 3   NCT06456567   United States
      2023   Phase 1   NCT05687526   China
      2022   Phase 3   NCT05306574   Argentina;Australia;Bulgaria;Chile;Colombia;Germany;Guatemala;Hungary;Mauritius;Mexico;Philippines;Poland;Puerto Rico;Spain;United States
      2022   Phase 1   NCT05247203   China
   RenJi Hospital
      2024   -   NCT06394063   China
   Ruijin Hospital of Shanghai Jiao Tong University
      2022   Phase 4   ChiCTR2200058379   China
   The First Affiliated Hospital of Nanjing Medical University
      2023   Phase 4   ChiCTR2300074080   China
   The First Affiliated Hospital of Wenzhou Medical University
      2022   Phase 4   ChiCTR2400086874   China
   The First Hospital of China Medical University
      2022   Phase 4   ChiCTR2200062250   China
   West China Hospital of Sichuan University
      2024   Phase 1   ChiCTR2400086819   China
   Xuzhou NO.1 People's Hospital
      2022   Phase 4   ChiCTR2200064438   China
Telitacicept 160MG
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2024   Phase 4   NCT06677801   China
Thalidomide
   University of Sao Paulo General Hospital
      2017   Phase 4   NCT03122431   Brazil
THE generic name IS warfarin and many producers will BE involved
   University College London
      2012   Phase 2   EUCTR2012-002345-38-GB   United Kingdom
Tissue sample
   University Hospital, Brest
      2023   -   NCT05747651   France
      2022   Phase 3   NCT05458622   France
TJ202 injection
   TJ Biopharma Co., Ltd.
      2021   Phase 1   NCT05140824   China
Tocilizumab
   Hoffmann-La Roche
      2023   Phase 1   NCT05835986   Colombia;France;Germany;Malaysia;Mexico;Netherlands;Peru;Poland;South Africa;Spain;Taiwan;Thailand;United Kingdom
      2022   Phase 1   NCT05155345   Georgia;Moldova, Republic of;Poland;Ukraine;United States
   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
      2023   Phase 1   NCT05869955   Belgium;France;Germany;Italy;Spain;United States
Tocopherol acetate
   Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
      2014   Phase 2   JPRN-UMIN000008230   Japan
   Nakashima Yasuharu
      2014   Phase 2   JPRN-jRCTs071180052   -
Tofacitinib
   Children's Hospital Medical Center, Cincinnati
      2017   Phase 1/Phase 2   NCT03288324   United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1   NCT05048238   United States
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2015   Phase 1   NCT02535689   United States
Tofacitinib citrate
   Tufts Medical Center
      2017   Early Phase 1   NCT03159936   United States
Total body irradiation
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 1/Phase 2   NCT02080195   United States
TQB3702 tablets
   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      2025   Phase 2   NCT06859931   China
      2024   Phase 1   NCT06448273   China
Trade name xarelto
   University College London
      2019   Phase 2;Phase 3   EUCTR2018-001735-49-GB   United Kingdom
      2012   Phase 2   EUCTR2012-002345-38-GB   United Kingdom
Treatment :abacavir 600 MG/lamivudine 300 MG
   Hospices Civils de Lyon
      2024   Phase 2   NCT06356740   France
Trimethoprim-sulfamethoxazole
   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
      2017   Phase 4   NCT03042260   Mexico
Triptorelin pamoate
   Children's Hospital Medical Center, Cincinnati
      2003   Phase 2   NCT00124514   Brazil;United States
TRU-015
   Wyeth is now a wholly owned subsidiary of Pfizer
      2007   Phase 1   NCT00479622   United States
TV-4710
   TEVA
      2005   -   EUCTR2005-001391-12-IT   Germany;Hungary;Italy;Spain;United Kingdom
   TEVA Pharmaceutical Industries, Ltd.
      2005   -   EUCTR2005-001391-12-HU   Germany;Hungary;Italy;Spain;United Kingdom
      2005   Phase 2   EUCTR2005-001391-12-GB   Germany;Hungary;Italy;Spain;United Kingdom
      2005   Phase 2   EUCTR2005-001391-12-ES   Germany;Hungary;Italy;Spain;United Kingdom
      2005   -   EUCTR2005-001391-12-DE   Germany;Hungary;Italy;Spain;United Kingdom
Ucar T-cell group
   Zhejiang University
      2025   Early Phase 1   NCT06920433   China
Ultrasonography assessment
   University Hospital, Bordeaux
      2021   -   NCT04276701   France;Germany;Spain
Upadacitinib
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 2   EUCTR2020-001690-72-IT   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000638-20-IT   Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
   AbbVie
      2023   Phase 3   NCT05843643   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Estonia;France;Germany;Greece;Guatemala;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2020   Phase 2   NCT04451772   Argentina;Australia;Bulgaria;Canada;China;Colombia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   NCT03978520   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States
   AbbVie Deutschland GmbH & Co. KG
      2021   Phase 2   EUCTR2020-001690-72-DE   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001690-72-BG   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001690-72-NL   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001690-72-HU   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000638-20-NL   Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000638-20-DE   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-000638-20-BG   Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000638-20-HU   Argentina;Australia;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-000638-20-ES   Argentina;Australia;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States
   Otani Tetsuya
      2023   Phase 3   JPRN-jRCT2061230060   Japan;United States
   Yamazaki Hayato
      2021   Phase 2   JPRN-jRCT2031210119   Argentina;Bulgaria;China;Germany;Hungary;Japan;Mexico;Netherlands;Poland;Puerto Rico;Spain;Taiwan;United States
Urinalysis
   LiveKidney.Bio
      2025   Phase 1   NCT06737380   United States
Urine sample
   University Hospital, Bordeaux
      2018   -   NCT03575156   France
   University Hospital, Brest
      2023   -   NCT05747651   France
      2022   Phase 3   NCT05458622   France
Ustekinumab
   Janssen Research & Development, LLC
      2020   Phase 3   NCT04060888   China
   Janssen-Cilag International N.V.
      2015   Phase 2   EUCTR2014-005000-19-PL   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-005000-19-HU   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-005000-19-ES   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
      2015   Phase 2   EUCTR2014-005000-19-DE   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States
   Janssen-Cilag International NV
      2019   Phase 3   EUCTR2017-001489-53-PT   Argentina;Bulgaria;Canada;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-PL   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-LT   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-HU   Argentina;Australia;Bulgaria;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-ES   Argentina;Australia;Bulgaria;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-DE   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
      2018   Phase 3   EUCTR2017-001489-53-BG   Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
Ustekinumab 90 MG
   Janssen Research & Development, LLC
      2018   Phase 3   NCT03517722   Argentina;Australia;Bulgaria;Canada;China;Colombia;Ecuador;France;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States
Ustekinumab IV
   Janssen Research & Development, LLC
      2015   Phase 2   NCT02349061   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United Kingdom;United States
Ustekinumab SC
   Janssen Research & Development, LLC
      2015   Phase 2   NCT02349061   Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United Kingdom;United States
UTAA91 injection
   PersonGen BioTherapeutics (Suzhou) Co., Ltd.
      2025   Early Phase 1   NCT06970951   China
Vaccination
   Tuen Mun Hospital
      2015   -   NCT02477254   China
      2009   Phase 4   NCT00911521   China
Vaccine
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 2   NCT01072734   France
   Tel-Aviv Sourasky Medical Center
      2009   Phase 2   NCT01006681   -
   University Medical Center Groningen
      2007   -   EUCTR2007-004579-21-NL   Netherlands
VAY736
   NOVARTIS PHARMA AG
      2023   Phase 3   EUCTR2022-002690-29-IT   Argentina;Australia;Chile;Colombia;France;Germany;India;Italy;Korea, Republic of;Mexico;Romania;Taiwan;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2022   Phase 3   EUCTR2022-002691-36-ES   Brazil;Bulgaria;Canada;China;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Turkey;United States
      2018   Phase 2   EUCTR2018-001508-12-ES   Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand
   Novartis Pharma AG
      2023   Phase 3   EUCTR2022-002691-36-SK   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Turkey;United States
      2023   Phase 3   EUCTR2022-002691-36-PT   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Türkiye;United States
      2023   Phase 3   EUCTR2022-002691-36-PL   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Türkiye;United States
      2023   Phase 3   EUCTR2022-002691-36-HU   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Turkey;United States
      2023   Phase 3   EUCTR2022-002691-36-CZ   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Turkey;United States
      2023   Phase 3   EUCTR2022-002691-36-BG   Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Guatemala;Hungary;Israel;Japan;Poland;Portugal;Slovakia;South Africa;Spain;Thailand;Türkiye;United States
      2023   Phase 3   EUCTR2022-002690-29-RO   Argentina;Australia;Chile;Colombia;France;Germany;India;Italy;Korea, Republic of;Mexico;Romania;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002690-29-FR   Argentina;Australia;Chile;Colombia;France;Germany;India;Italy;Korea, Republic of;Mexico;Romania;Taiwan;United Kingdom;United States
      2023   Phase 3   EUCTR2022-002690-29-DE   Argentina;Australia;Chile;France;Germany;India;Italy;Korea, Republic of;Mexico;Romania;South Africa;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-001508-12-FR   Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand
      2018   Phase 2   EUCTR2018-001508-12-DE   Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States
      2018   Phase 2   EUCTR2018-001508-12-CZ   Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States
   Novartis Pharmaceuticals
      2018   Phase 2   NCT03656562   Argentina;Australia;China;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States
VAY736 1ML PFS
   Novartis Pharmaceuticals
      2024   Phase 2   NCT06293365   Argentina;Canada;Czechia;Hungary;Italy;Poland;Spain;United States
VAY736 2 ML PFS
   Novartis Pharmaceuticals
      2024   Phase 2   NCT06293365   Argentina;Canada;Czechia;Hungary;Italy;Poland;Spain;United States
VAY736 2ML AI
   Novartis Pharmaceuticals
      2024   Phase 2   NCT06293365   Argentina;Canada;Czechia;Hungary;Italy;Poland;Spain;United States
VIB7734
   Amgen
      2021   Phase 2   NCT04925934   Argentina;Greece;India;Mexico;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2018   Phase 1   NCT03817424   Poland;Spain;United States
VIB7734, MEDI7734
   Viela Bio, Inc.
      2021   Phase 2   EUCTR2020-005528-12-ES   Argentina;Greece;India;Mexico;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
VIP
   MONDOGEN AG
      2008   -   EUCTR2007-003621-24-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
   MondoGEN AG
      2009   -   EUCTR2007-003621-24-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-003621-24-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-003621-24-GB   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-003621-24-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-003621-24-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2008   -   EUCTR2007-003621-24-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
VIS171
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2025   Phase 1   NCT06799520   Moldova, Republic of
Vitamin D
   The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
      2017   -   ChiCTR-INR-17011495   China
Vitamin D 25(OH)D
   Faculty of Medicine, University of Alexandria
      2010   -   NCT01425775   Egypt
Vitamin D2
   Rajavithi Hospital
      2021   -   NCT05260255   Thailand
Vitamin D3
   Dr Cipto Mangunkusumo General Hospital
      2021   Phase 3   NCT05326841   Indonesia
   National Institute of Allergy and Infectious Diseases (NIAID)
      2008   Phase 2   NCT00710021   United States
Vitamin D3 400 IU
   National Institute of Allergy and Infectious Diseases (NIAID)
      2013   Phase 2   NCT01709474   United States
Vitamin D3 6000 IU
   National Institute of Allergy and Infectious Diseases (NIAID)
      2013   Phase 2   NCT01709474   United States
Vitamins: B6, B12, and folate
   Brigham and Women's Hospital
      2003   Phase 2   NCT00054938   United States
Vobarilizumab
   Ablynx N.V.
      2015   Phase 2   EUCTR2015-000372-95-HU   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2015   Phase 2   EUCTR2015-000372-95-DE   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
      2015   Phase 2   EUCTR2015-000372-95-CZ   Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States
Voclosporin
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 2   NCT05306873   United States
Vunakizumab
   Chinese SLE Treatment And Research Group
      2025   Phase 1   NCT06881290   -
Warfarin
   University College, London
      2021   Phase 2   NCT03684564   United Kingdom
Warfarin sodium
   University College London
      2019   Phase 2;Phase 3   EUCTR2018-001735-49-GB   United Kingdom
Without anticoagulation
   Qilu Hospital of Shandong University
      2018   Phase 1   NCT04976465   China
XMAB5871
   Xencor, Inc.
      2016   Phase 2   NCT02725515   United States
YTB323
   Novartis Pharma AG
      2023   Phase 1;Phase 2   EUCTR2022-001796-14-FR   Australia;France;Germany;Spain;United States
      2023   Phase 1;Phase 2   EUCTR2022-001796-14-DE   Australia;France;Germany;Spain;United States
   Novartis Pharmaceuticals
      2023   Phase 1/Phase 2   NCT05798117   Australia;France;Germany;Spain;Switzerland;United States
YTS109 cell
   China Immunotech (Beijing) Biotechnology Co., Ltd.
      2025   Phase 1   NCT06978647   -
YTS109 cell injection
   China Immunotech (Beijing) Biotechnology Co., Ltd.
      2025   Phase 1   NCT06943937   China
YU-tone music intervention
   Yijun Luo
      2025   -   NCT06898489   China
Zamtocabtagene autoleucel
   Miltenyi Biomedicine GmbH
      2025   Phase 1   NCT06708845   -
Zishenqing
   Shanghai University of Traditional Chinese Medicine
      2019   Phase 2/Phase 3   NCT04275193   China
ZM001 injection
   Beijing Immunochina Medical Science & Technology Co., Ltd.
      2025   Phase 1   NCT06852573   -
Zostavax
   Tuen Mun Hospital
      2015   Phase 4   NCT02477150   China
Zostavax vaccine
   Oklahoma Medical Research Foundation
      2011   Phase 1   NCT01474720   United States